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GENERAL INTRODUCTION 
Thesis Organization 
This thesis begins with a general introduction including a statement of the research 
problem, followed by a review ofliterature, a manuscript, general conclusions, and a list of 
references for the introduction and review of literature. 
Objectives, Hypotheses, Specific Aims, Limitations, 
and Significance of Proposed Study 
Objectives 
The purpose of this 24-week study was to determine whether isoflavone-rich soy 
protein reduces the risk of cardiovascular disease (CVD) by favorably altering plasma lipid 
and lipoprotein concentrations, coagulation and fibrinolytic factors, and oxidative balance in 
perimenopausal women. 
Hypotheses 
Due to the estrogen-like characteristics of isoflavones, isoflavone-rich soy protein 
will reduce CVD risk factors by: 
1. Favorably altering lipid/lipoprotein concentrations 
a. by lowering total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), 
triacylglycerol (TG), TC/ high density lipoprotein cholesterol (HDL-C) ratio and 
b. by increasing HDL-C. 
2. Improving total antioxidant status. 
3. Favorably altering coagulation/fibrinolytic factors by lowering lipoprotein(a) [Lp(a)], 
fibrinogen, factor VII antigen, and plasminogen activator inhibitor-I (P AI-1 ). 
Specific aims 
1. To determine whether 24 weeks of isoflavone-rich soy protein intake exerts an 
estrogen-like effect on CVD risk factors in perimenopausal women by assessing 
changes in: 
a. Lipid and lipoprotein concentrations, 
b. Total antioxidant status, and 
c. Coagulation and fibrinolytic factors. 
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2. To determine the collective contribution of circulating coagulation/fibrinolytic and 
other factors (such as dietary intake of selected nutrients; serum estrogens, ferritin, 
iron, liver enzymes; body size/composition; blood pressure; and physical activity) to 
plasma lipids and lipoproteins at baseline in these perimenopausal women. 
Limitations 
Perimenopause is a transition period during which hormones may dramatically 
fluctuate. Thus, one limitation of our study may have been that the hormonal changes during 
the menopausal transition could have had an overriding effect on some of the cardiovascular 
end points. Alternatively, the stage at which we obtained blood samples may have been too 
early in the menopausal transition to reveal marked adverse effects on circulating 
lipids/lipoproteins or coagulation/fibrinolytic factors, thus making it more difficult to 
demonstrate an effect of treatment. Matthews et al. (1994) reported that perimenopausal 
women did not have more adverse lipid/lipoprotein profiles when compared with 
premenopausal controls. Significant changes have been noted once perimenopausal women 
become postmenopausal (Matthews et al. 1994), suggesting that our six-month study may 
have been too short to have fully captured the potential treatment-induced changes in the 
lipid/lipoprotein profile. Also, differences among individuals in absorption (Xu et al. 1995) 
and metabolism (Kelly et al. 1995) of isoflavones may influence the response to treatment. 
Significance of proposed study 
Despite the uncertainty of the exact time point at which lipid-related CVD risk factors 
increase, perimenopause has been identified as a critical period in which to initiate preventive 
efforts (Matthews et al. 1994 ). The effect of soy with isoflavones on the lipid/lipoprotein 
profile of postmenopausal women has been examined (Potter et al. 1998), but we know very 
little about the effect during the perimenopausal period. Also, soy isoflavone treatment in 
relation to the antioxidant activity in perimenopausal women has not been documented. 
Information is available on the effects of soy isoflavones on coagulation/fibrinolytic factors 
in vitro (Wilcox and_Blumenthal 1995), but there are no published data on the in vivo effects. 
If this study indicates that soy protein with isoflavones improves the lipid profile, improves 
and/or maintains antioxidant status, and/or favors fibrinoly_sis, this could serve as an 
alternative or adjuvant treatment during menopause. This may be most important for women 
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who are poor candidates for, or chose not to take, estrogen replacement therapy (ERT) or 
hormone replacement therapy (HRT). 
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REVIEW OF LITERATURE 
Overview of Cardiovascular Disease Risk Factors in Women 
All forms of cardiovascular disease lead to more than 50 percent of all deaths among 
women each year, accounting for over 500,000 deaths in the United States (Giardina 1998). 
Atherosclerotic CVD is a major contributor to this mortality statistic. Atherosclerosis is the 
underlying process leading to the clinical sequelae of coronary heart disease (CHD), 
cerebrovascular disease, and peripheral vascular disease. Recent investigations have 
identified both non-mo~ifiable and modifiable CVD risk factors that more directly relate to 
women's health. 
Non-modifiable risk factors 
Non-modifiable risk factors include sex, age, race, and family history. Premenopausal 
women have one-third the incidence of CHD than men of the same age. Although overall 
morbidity and mortality for women is less than that of males for CHD, the morbidity rate is 
greater for postmenopausal women than for males of similar age (Lerner and Kannel 1986). 
Age is considered a major risk factor for CVD in women, since mortality from CVD 
increases approximately 50 percent for each succeeding five-year age group (Vital Statistics 
of the United States 1987). Race also influences CVD as illustrated by young adult and mid-
life African-Americans having nearly twice the number of deaths compared with their 
Caucasian counterparts. In contrast, Asian and Hispanic adults have nearly half the number 
of CVD-related deaths compared with similarly aged Caucasians. However, after 65 years of 
age, mortality among Caucasians matches that of their African-American counterparts. After 
age 65, Asian and non-black Hispanics have the lowest CVD mortality rates, approximately 
half that of Caucasians (National Center for Health Statistics 1991). Family history is a 
strong risk factor for young women; increased death due to CHD occurs in women whose 
first-degree female relatives have been diagnosed with CVD before 55 years of age (Slack 
and Evans 1966). If the onset of CVD is after the age of 55, there is no clear association with 
family history (Higgins et al. 1987). 
Modifiable risk factors 
Modifiable risk factors include elevated blood pressure, smoking, dyslipidemia, 
obesity, diabetes, and physical inactivity. As a woman ages, she actually has a greater chance 
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of developing high blood pressure than a man (Legato 1991). Cigarette smoking is 
considered the single most preventable cause of heart disease in this country. Smoking has a 
dose-dependent effect on the number of deaths due to CVD, with 10 and 20 cigarettes per 
day increasing the risk of CVD-related death by 50 and 100 percent, respectively (Bush and 
Comstock 1983). Quitting smoking helps to reduce the risk of death by CVD, perhaps to that 
of a nonsmoker (Redberg 2000). Plasma lipoprotein levels are useful for diagnosing CVD, 
with lipid risk factors being elevated TC, LDL-C (particularly oxidized LDL), TG, and 
Lp(a), and low HDL-C. Age, hormonal status, body composition and weight, physical 
activity, and diet influence these lipid risk factors. Dietary intake, through excessive energy, 
influences CVD risk by contributing to dyslipidemia, obesity, and perhaps diabetes. Also, 
diet influences CVD risk via fat (total amount and type) consumption that alters 
lipid/lipoprotein profiles. The inclusion of supplements and/or foods containing antioxidants 
has been shown to prevent the harmful oxidation of lipids/lipoproteins (Jialal and Fuller 
1995; Chopra and Thurnham 1999; Weisburger 1999). Physical inactivity is a common 
finding among CVD patients. More than 50 percent of women do not exercise at all, placing 
them at an increased risk for developing CVD (Redberg 2000). Researches have concluded 
that physical inactivity is an independent risk factor for CVD by demonstrating the protective 
effect of leisure time physical activity on coronary death in men (Rosengren and Wilhelmsen 
1997). 
Recently identified risk factors 
Two more recently identified risk factors that are directly associated with CVD -
coagulation/fibrinolytic factors and total antioxidant status - are currently under 
investigation. Coagulation factors include fibrinogen and factor VII. The factors that 
influence the fibrinolytic pathway are Lp(a) and PAI-1. Fibrinogen is a plasma protein 
responsible for inducing the formation of blood clots. Factor VII is involved in inducing clot 
formation and increases with age and during the menopausal transition. Lipoprotein(a) is 
considered both a thrombotic risk marker and an atherogenic lipoprotein. If elevated, Lp(a) is 
associated with an increased risk of CVD since Lp(a) interferes with plasmin production. 
Genetics is the primary determinant ofLp(a) concentrations, although hormonal changes that 
occur during menopause may elevate Lp(a) (Mijatovic et al. 1997). Plasminogen activator 
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inhibitor-1 also interferes with the formation of plasmin. The appropriate balance between 
coagulation and fibrinolytic factors is critical in atherogenesis. Response to injury involves 
the coagulation pathway and may lead to thrombi formation and hence blockage of an artery. 
Fibrinolytic factors are involved in countering this thrombotic event. 
Oxidative stress plays a role in the development of CVD since oxidized LDL particles 
induce atherogenesis. Supplemental antioxidants have been shown to reduce the level of 
oxidative stress, thus reducing the clinical manifestations of atherosclerosis (Diaz et al. 
1997). The antioxidant defense system may be compromised after menopause, with an 
increase in lipid peroxidation. This places postmenopausal women at higher risk for CVD 
than their premenopausal counterparts. 
Effect of menopause 
The several years during which ovarian function begins to decline is defined as 
perimenopause (Klein and Soules 1998). The perimenopausal period is associated with 
irregular menses or cessation of menses for less than one year and in some women vasomotor 
symptoms (such as hot flushes and/or night sweats) (Greendale et al. 1999) due to the · 
reduction of 17 f.3-estradiol. Postmenopause is defined as cessation of menstruation for 
greater than 12 months (WHO 1981). During the postmenopausal period, the primary source 
of estrogen is androstenedione secreted from the adrenal cortex, which is converted to 
estrone by adipose tissue, skeletal muscle, liver, brain, kidney, and hair follicles (Lievertz 
1987). These hormonal changes during menopause predispose women to CVD, as evidenced 
by the higher incidence for postmenopausal than premenopausal women. Hormone 
replacement therapy after menopause is protective against CHD and stroke (NCEP 1993). 
Women with intact uteri must be protected from endometrial hyperplasia with ER T use by 
the addition ofprogestins. Estrogen and progestogen combined has a less well-understood 
effect on CVD risk. Hormone replacement therapy has been shown to favorably alter LDL-C 
and HDL-C/LDL-C ratios (Speroff et al. 1996; PEPI 1995), decrease fibrinogen (Vorster 
1999), and enhance fibrinolytic activity (Lijnen and Collen 1996). The antioxidant effect of 
17 f.3-estradiol has been shown in vitro to inhibit LDL oxidation (Huber et al. 1990). 
Although HRT is beneficial in reducing CVD risk, HRT has some adverse side effects and 
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may induce non-compliance due to continued bleeding in many women, as well as the fear of 
cancer (Samsioe 1996). 
Soy protein with isoflavones 
A potential alternative to HRT may be a diet high in plant-based foods that have been 
linked epidemiologically to lower occurrence of hormone-dependent diseases, such as CVD 
and some types of cancer (Setchell and Cassidy 1999). Soybeans contain a class of 
phytoestrogens called isoflavones. The major dietary isoflavones are the glycosides of 
genistein and daidzein. It has been shown in vitro and in vivo that isoflavones, particularly 
genistein, exert a weak estrogenic effect (Mayr et al. 1992). Numerous studies have 
documented that soy protein, particularly in conjunction with isoflavones, exert a 
hypocholesterolemic effect (Sirtori 1995; Anthony et al. 1996; Balmir et al. 1996). Potter et 
al. (1998) demonstrated a positive effect, whereas three studies (Hodgson et al. 1998; Simons 
et al. 2000; Nestel et al. 1999) have reported· no effect of isoflavones alone on lipid profiles 
of postmenopausal women. Whether a beneficial effect can be replicated in perimenopausal 
women (Washburn et al. 1999) will require further research. The examination of the effect of 
soy protein with isoflavones on coagulation factors is limited, with a couple of studies 
showing no effect on Lp(a) in normocholesterolemic women (Hodgson et al. 1998; 
Yamashita et al. 1998) and one in vitro study indicating that genistein induces fibrinolytic 
enzyme activity (Sitter et al. 1996). Like estrogen, isoflavones exert antioxidant properties 
(Nairn et al. 1976); however, the ability ofisoflavones in vivo to affect total antioxidant 
status during menopause has not been documented. 
Characteristics, Metabolism, and Factors Affecting Lipids/Lipoproteins 
Plasma lipoproteins: Characteristics; menopause, estrogen/hormone replacement 
therapy, and soy 
This section examines plasma lipoproteins and their associated apolipoproteins in 
relation to CVD risk during menopause. Lipoproteins have similarities in structure, which is 
described as a whole, along with their interrelated function, formation, and metabolism. 
Clinical manifestations of impaired lipid/lipoprotein metabolism and its involvement in the 
development of CVD are reviewed next. The relationship between plasma lipoproteins and 
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estrogen is addressed in the context of usual changes experienced during menopause. The 
effects ofERT/HRT and soy protein containing isoflavones on the lipid profile throughout 
menopause conclude this section. 
Lipoproteins and their associated apolipoproteins 
Plasma lipoproteins and apolipoproteins are synthesized in the liver and the intestinal 
mucosal cells. Lipoproteins are circulating complexes oflipid packaged with apolipoproteins, 
the latter allowing them to be water-soluble and readily transported. Apolipoproteins not only 
facilitate transport, but also serve a structural role in maintaining the integrity of lipoproteins, 
and as recognition sites for receptors, thereby directing the metabolic fate of lipoproteins 
(Davis 1997; Olson 1998). 
Classification of lipoproteins is based upon two methods: electrophoresis and 
ultracentrifugation. Classes defined by electrophoresis are chylomicrons, prebeta, broad beta, 
and alpha lipoproteins. Using ultracentrifugation, five classes analogous to the previous 
method are defined as chylomicrons, very low density lipoproteins (VLDL), intermediate 
density lipoproteins (IDL), LDL-C, and HDL-C (Olson 1998; Alaupovic 1996). The latter 
nomenclature is most commonly used today. 
Apolipoproteins are grouped according to their function. They are classified into 
groups A, B, C, D, and E. Each class contains several subclasses of proteins; for example, 
class A is comprised of A-I, II, III, and IV (Chappell and Spector 1991). Apolipoproteins in 
class A are associated with HDL and nascent chylomicrons, whereas those in class D are 
found only with HDL. Class B apolipoproteins are associated with chylomicrons, VLDL, 
IDL, and LDL, whereas those in class C are predominately associated with VLDL and HDL. 
Apolipoproteins in class E are associated with VLDL, IDL, and chylomicron remnants 
(Alaupovic 1996). 
Structure. Lipoproteins have a similar structure upon maturation in the circulation, 
with various proportions ofTG and cholesteryl esters in the core, as well as different 
proportions of apolipoproteins, phospholipids, and free cholesterol in the hydrophilic outer 
shell (Basile-Borgia and Abel 1996). Phospholipids and cholesterol are important in cell 
membrane synthesis and integrity, whereas TG are the main· source of energy for peripheral 
tissue. Chylomicrons are the least dense of the lipoproteins with a density of 0.920 to 0.960 
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g/ml. The composition of this lipoprotein by weight is as follows: 87% TG, 8% 
phospholipid, 1.5% free cholesterol, 2% cholesteryl esters, and 1. 7% protein. The diameter of 
chylomicrons ranges from 75 to 600 nanometers (nm). The major apolipoproteins imbedded 
in the phospholipid-cholesterol surface are apolipoproteins B-48, A-I, and A-IV. Very low 
density lipoproteins are structurally similar to chylomicrons, but are denser and smaller; their 
density ranges from 0.950 to 1.006 g/ml and their diameter from 28 to 75 nm. The particle 
content ofVLDL by weight is 55% TG, 20% phospholipid, 10% free cholesterol, 5% 
cholesteryl esters, and 9% protein. The major apolipoproteins imbedded in the phospholipid-
cholesterol surface ofVLDL are apolipoprotein B-100, C-I, II and III. Intermediate density 
lipoproteins are smaller and denser than VLDL, with a diameter of approximately 21 nm and 
a density ranging from 1.006 to 1.019 g/ml. The particle content ofIDL by weight is 20% 
TG, 18% phospholipid, 25% cholesteryl esters, 20% free cholesterol, and 18% protein. The 
apolipoproteins B-100 and E are associated with the IDL particle. The particle content of 
LDL is 8%TG, 24% phospholipid, 8% free cholesterol, 35% cholesteryl esters, and 25% 
protein. The density ofLDL ranges from 1.019 to 1.063 g/ml and these particles have a 
diameter of 17 to 26 nm. The core of LDL is primarily cholesteryl esters and a phospholipid-
cholesterol shell containing apolipoprotein B-100 derived from VLDL metabolism. Due to 
the heterogeneity ofLDL, these particles can be classified according to two different 
phenotypes, A and B. Low density lipoproteins in phenotype A are large and buoyant, 
whereas those in phenotype B are small and dense (Austin 1992). The composition of HDL is 
0.6% TG, 21 % phospholipid, 5% free cholesterol, 15% cholesteryl esters, and 55% protein. 
The density ofHDL ranges from 1.063 to 1.210 g/ml and HDL particles have a diameter of 
about 10.8 nm. Newly synthesized HDL contain apolipoproteins E, A-I, II, III, and a 
phospholipid-cholesterol bilayer (Olson 1998; Ginsberg 1998). Subclasses ofHDL exist, 
differing by which apolipoprotein(s) they contain, which in turn determines the unique 
cholesteryl ester content of each subclass (Olson 1998). The subclass HDL3 accepts free 
cholesterol from peripheral tissues. After accumulating cholesterol, HDL3 enlarges and gains 
additional apolipoproteins. Enzymatic reactions then convert HDL3 into HDL2 (Basile-
. Borgia and Abel 1996). 
Function. Lipoproteins function primarily to mediate the flux of lipid and 
cholesterol among the liver, intestine, adipose, muscle, and other tissues (Alaupovic 1996). 
Lipoproteins are also recognized as playing a role in immune function and coagulation 
(Chambaud et al. 1999; Rosenson and Lowe 1998). The individual lipoproteins are discussed 
with regard to their unique involvement in lipid transport. Chylomicrons package dietary 
fatty acids from the intestine and transport TG to tissues, whereas VLDL transport TG 
derived from the liver to extrahepatic tissues. Triacylglycerol from VLDL may contain fatty 
acids synthesized by the liver from glucose ( or other sources of acetyl coenzyme A) or fatty 
acids ~xtracted from the blood by the liver and serve as an initial product formed in VLDL 
catabolism. Intermediate density lipoproteins serve as an initial product formed during VLDL 
catabolism. Cholesterol transport is the main function ofLDL (Griffin 1999). During their 
residence time in circulation, LDL engulf cholesterol and then deliver it to extrahepatic 
tissues. In contrast, HDL transport lipids and apolipoproteins during the metabolism of TG-
rich lipoproteins. Specifically, HDL are key in reverse cholesterol transport since these 
particles take up cholesterol from extrahepatic tissues and carry cholesterol to the liver for 
degradation and eventual removal (Basile-Borgia and Abel 1996). 
Formation and metabolism. Chylomicrons are synthesized in the intestine after the 
ingestion of dietary fat. Bile acids.and pancreatic enzymes in the intestine emulsify dietary 
TG and cholestryl esters into fatty acids, 2-monoacylglycerides, and cholesterol. The amount 
of dietary fat consumed dictates the size of the chylomicron. Cholesterol needed to form 
chylomicrons may also arise from de novo synthesis or from cholesterol transferred from 
other lipoproteins present in the lymph and plasma. These products are passively absorbed 
into the mucosa} cell; TG are .resynthesized in the smooth endoplasmic reticulum. Micelles 
are formed in the intestine after the addition of cholesterol and phospholipids. 
Apolipoproteins B-48, A-I, A-II, and A-IV synthesized in the rough endoplasmic reticulum 
are combined with lipid to make a newly synthesized chylomicron. Apolipoprotein B-48 is 
required for chylomicron synthesis and contributes to the stability of the lipoprotein. After 
formation, chylomicrons enter the lymph system and enter the general circulation via the 
. thoracic duct. As chylomicron metabolism begins, modifications to apolipoproteins are 
made, such as loss of apolipoproteins A-I and IV to HDL and the acquisition of 
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apolipoprotein E. Complete chylomicron metabolism yields a chylomicron remnant, which 
has lost TG, apolipoprotein C, some apolipoprotein E, but has retained apolipoprotein Band 
acquired some cholesteryl esters. Retention of apolipoproteins B and E is crucial for the 
hepatic uptake and degradation of the remnant via phagocytosis (Ginsberg 1998). Specific 
remnant receptors in the liver recognize apolipoprotein B-48- and E-containing lipoproteins 
and are termed 'apolipoprotein E receptors'. Circulating lipoprotein remnants can bind to the 
LDL receptor via apolipoprotein E (Olson 1998). The next step is the uptake of the remnant 
by LDL receptors and/or LDL receptor-related proteins by classical receptor-mediated 
endocytosis (Chappell and Medh 1998; Havel 1998). 
The origin ofVLDL and chylomicron synthesis differs; chyloniicrons are produced in 
the intestine, whereas VLDL are synthesized in the liver. The TG core ofVLDL is derived 
from the liver rather than dietary fat. Triacylglycerol from VLDL may contain fatty acids 
synthesized by the liver from glucose ( or other somces of acetyl coenzyme A) or fatty acids 
extracted from the blood by the liver. Metabolism of VLDL is similar to chylomicron 
metabolism with the result being TG removal. After production in the liver; the newly 
synthesized nascent VLDL particle enters the circulation. Newly synthesized VLDL have 
two fates: 1) removal from circulation into the liver by specific receptors on hepatocyte cell 
membranes, or 2) conversion into smaller, denser, cholesterol-rich LDL (Young and 
Parthasarathy 1994 ): Metabolism causes changes such as the addition of apolipoproteins C 
and E, with retention of apolipoprotein B-100. After further metabolism, fatty acids are 
released, the TG core is reduced, cholesteryl esters are gained, and a fraction of 
apolipoproteins E and Care lost. The initial product ofVLDL catabolism is IDL, but not all 
VLDL particles experience complete catabolism past this intermediate 'remnant' form. 
About half of the VLDL particles are cleared from the circulation by specific hepatic 
receptors. The early phase ofVLDL remnant clearance may be due to hepatic sequestering 
and/or apolipoprotein E-mediated binding (Eisenberg and Sehayek 1995). The remaining 
IDL particles _undergo rapid turnover to LDL; within two to six homs from the time they first 
appear, IDL are no longer present in plasma. 
After the final processing ofVLDL remnants, LDL particles evolve from enzymatic 
action in the plasma. Compared with TG-rich lipoproteins, LDL have a longer residence time 
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of two to three days. Small VLDL and LDL bind to hepatic LDL receptors via apolipoprotein 
B-100 and are thus removed from the circulation. The presence of other apolipoproteins, C-
HI and E, has been shown to impair the interaction of apolipoprotein B with the LDL 
receptor, suggesting that apolipoprotein E participates instead in the LDL receptor binding 
(Clavey et al. 1991). After binding, LDL are removed from the circulation by incorporation 
into intracellular clathrin-coated vesicles with subsequent digestion in lysosomes. The liver 
removes 60 to 70 percent ofLDL, whereas other tissues expressing LDL receptors remove 
the remaining LDL particles. Overall, LDL-C concentrations depend on the rates of 
conversion ofVLDL to LDL and subsequent LDL clearance (Grundy 1995). 
High density lipoproteins are synthesized from protein and phospholipids secreted by 
the intestine and liver. The small particle size ofHDL allows it to easily cross the vascular 
endothelium. After entering the circulation, HDL lose some of their apolipoproteins C and E, 
gain apolipoprotein A, and free cholesterol is converted to cholesteryl esters. During TG 
uptake, apolipoprotein C is acquired along with phospholipid and cholesterol (Ginsberg 
1998). Through the metabolic process of reverse cholesterol transport, HDL accumulates 
cholesterol from extrahepatic tissues. The HDL particle is capable of reverse cholesterol 
transport as described by an aqueous diffusion model and/or an HDL receptor. Through 
aqueous diffusion, free cholesterol from HDL and cell membranes form between them an 
aqueous phase. Either the cell or the HDL particle then resorbs the cholesterol. The net 
movement of cholesterol to either the cell or HDL depends on the phospholipid content of 
HDL; phospholipid-rich HDL readily accepts free cholesterol. The HDL receptor model 
proposes that cells having HDL receptors, thus permitting the transfer of cholesterol out of 
the cell, accomplish cholesterol removal. The final step in the reverse cholesterol transport 
pathway is the removal of cholesteryl esters contained in VLDL, IDL, and LDL through LDL 
receptors in various tissues (Olson 1998). The cholesterol is then either: 1) excreted in bile 
or 2) secreted back into circulation via nascent lipoproteins. The HDL particle is cleared by 
LDL receptors if it is emiched with apolipoprotein E, or the particle may be removed by a 
distinct HDL receptor (Kwiterovich, Jr. 1998). Thus, HDL-C concentrations may be 
indicative of the reverse cholesterol transport activity. The concentration ofHDL-C depends 
on: 1) apolipoprotein rate of synthesis, 2) rates of free cholesterol esterification to 
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cholesteryl ester, 3) concentrations of TO-rich lipoproteins and transfer of cholesteryl esters 
from HDL, and 4) clearance ofHDL lipids and apolipoproteins from plasma (Ginsberg 
1998). Table 1 lists the reference ranges for lipid/lipoprotein concentrations. 
Table 1. Reference ranges for lipids/lipoproteins for women over 40 years of age 
Lipid/lipoprotein 
Total cholesterol1 
Low density lipoprotein 
cholesterol 1 
High density lipoprotein 
cholesterol 1 
. 1 
Triacylglycerol 
Total cholesterol/high 
Present reference range 
and units 
<265 mg/dL 
50- 190 mg/dL 
30-90 mg/dL 
<160 mg/dL 
<5.60 
density lipoprotein cholesterol2 
1 From Young 1998 
2 From Kinosian et al. 1994 
SI reference range 
and units 
<6.85 mmol/L 
1.30 - 4.90 mmol/L 
0.80 - 2.35 mmol/L 
<1.80 mmol/L 
<5.60 
Enzymes and related proteins. Several enzymes are involved in lipoprotein 
metabolism including lipoprotein lipase, hepatic lipase, lecithin-cholesterol acyltransferase, 
and cholesteryl ester transfer protein. Lipoprotein lipase is the key enzyme involved in the 
delivery of fatty acids (Fielding and Frayn 1998). The synthesis of lipoprotein lipase occurs 
in the interior of either the capillary endothelial cells or the parenchymal cells in various 
tissues (Beisiegel 1996). Lipoprotein lipase then migrates into the vasculature, where it 
adheres tightly to heparan-like polysaccharide chains on endothelial cell surfaces (Ginsberg 
1998). Concentrations of lipoprotein lipase may vary due to changes in physiological and 
nutritional states, such as pregnancy and fasting (Fielding and Frayn 1998). Lipoprotein 
lipase is activated as it comes in contact with apolipoprotein C-II, which is donated by either 
VLDL or HDL. The hydrolysis ofTG and phospholipid is catalyzed by lipoprotein lipase 
(Jansen et al. 1998). This enzyme immediately hydrolyzes the TG in chylomicrons and 
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VLDL and transforms the lipoproteins into remnants. For example, the action oflipoprotein 
lipase on VLDL induces the loss ofTG resulting in LDL; this conversion takes place within a 
few hours ofVLDL appearance. Fatty acids are released from TG after transport through 
capillaries coated with lipoprotein lipase. This enzyme hydrolyzes either the one- or three-
ester bond of a TG and the one-ester bond of a diacylglyceride, releasing free fatty acid 
anions, which are carried through the plasma membrane of the recipient cell by a carrier 
protein. Once fatty acids are in the cell, they are converted to acyl coenzyme A and then 
further converted to TG for storage. Lipoprotein lipase is just one in a cascade of enzymes 
necessary for the deposition of fat into adipose tissue (Fielding and Frayn 1998). Besides 
lipoprotein lipase's role in lipid metabolism, a recent study has discovered that this enzyme, 
when expressed by cells such as macrophages in the vascular wall, could contribute to the 
formation of foam cells and atherosclerosis (Mead et al. 1999). 
Hepatic lipase is similar to lipoprotein lipase in that it also catalyzes the hydrolysis of 
TG and phospholipids (Ginsberg 1998). Crawford and Borensztajn (1999) have found that 
hepatic lipase, through non-receptor mediated uptake, can mediate endocytosis of 
chylomicron remnants independent of apolipoprotein E; thus hepatic lipase helps to regulate 
plasma clearance and liver uptake of chylomicron remnants. Hepatic lipase may also mediate 
the conversion ofHDL particles HDL2 to HDL3 (Beisiegel 1996). Concentration of hepatic 
lipase is increased by androgens and decreased by estrogens (Chappell and Spector 1991). 
The catalysis of cholesteryl esters is mediated by lecithin-cholesterol acyltransferase. 
The metabolic role oflecithin-cholesterol acyltransferase involves reverse cholesterol 
transport, in which the substrates are cholesterol and phosphatidyl-choline (Dobiasova and 
Frohlich 1998). Synthesized in the liver, lecithin-cholesterol acyltransferase binds to nascent 
HDL and esterifies cholesterol from a fatty acid donated by a phospholipid. Activation of 
lecithin-cholesterol acyltransferase does not occur until apolipoprotein A-I is transferred 
from a chylomicron to HDL. As the esters accumulate, they are transferred to other 
lipoproteins, such as delipidated chylomicrons and VLDL. These TG-rich lipoproteins in 
return donate TG to HDL through the action of a lipid transfer protein (Rueckert and Schmidt 
1990). A recent study shows that lecithin-cholesterol acyltransferase works in this protective 
manner only when the HDL2 fraction is present in high concentration. IfHDL2 concentration 
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is low, lecithin-cholesterol acyltransferase aids in the esterification of other lipoproteins, such 
as LDL, and may serve an atherogenic role in this instance (Dobiasova and Frohlich 1998). 
Cholesteryl ester transfer protein is another player in lipid metabolism. This protein 
transfers lipid among lipoproteins, but also takes up cholesterol directly from tissues. 
Depending on the situation, this enzyme can also have both proatherogenic and 
antiatherogenic roles (Ginsberg 1998). Genetic mutations leading to cholesteryl ester transfer 
protein deficiency, overexpression of cholesteryl ester transfer protein, or pre-existing 
disease, such as coronary artery disease (CAD), will determine whether this enzyme 
positively or negatively influences the atherosclerotic process (Stevenson 1998). 
Clinical manifestations of impaired metabolism 
Modification of lipoproteins and apolipoproteins occurs continuously. Metabolism of 
lipoproteins involves complex modifications, with abnormal synthesis and metabolism 
leading to the development of atherosclerotic CVD. The atherogenicity ofLDL is partially 
conferred by small dense LDL particles and not due to the transport of cholesterol per se· 
Small, dense LDL are significantly associated with increased coronary risk (Keys 1970; 
Kannel et al. 1971), likely due to increased cholesterol influx into the arterial wall because of 
its small, dense structure. The extracellular matrix attached to arteries binds small dense LDL 
with high affinity, sequestering these lipoproteins in a prooxidative environment, allowing 
cholesterol deposition. Low density lipoproteins have been found to be more susceptible to 
oxidative stress than the larger, less dense lipoproteins (Griffin 1999). Within the arterial 
wall, LDL particles are oxidized, with these particles then being taken up by macrophages, 
implicating oxidized LDL's involvement in the development of foam cells and eventual 
lesions (Young and Parthasarathy 1994). 
Increased levels of both VLDL and subsequently IDL are associated with the clinical 
features of premature atherosclerosis, glucose intolerance, and eruptive xanthomas. Plasma 
concentrations ofIDL are not normally identified due to rapid turnover, but IDL 
concentrations are used to define Type III hyperlipidemia. Overproduction and increased 
residence time allows more cholesterol deposition in the arterial wall (Griffin 1999). The 
atherogenic nature of these particles is thought to be due to their TG-rich core. Alterations in 
enzymes involved in lipid metabolism are related to impaired metabolism of atherogenic 
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lipoproteins; individuals with CHD have decreased lipoprotein lipase activity (Henderson et 
al. 1999). 
Overall, the greater the HDL-C concentration, the lower the CVD risk. This 
association ofHDL with antiatherogenicity is supported by a mechanism other than reverse 
cholesterol transport. This mechanism involves apolipoproteins A-I and two enzymes 
associated with HDL, paraoxanase and platelet-activating factor acetylhydrolase, which 
appear to reduce the formation of oxidized LDL (K witerovich, Jr. 1998). 
Menopause, estrogen/hormone replacement therapy, and soy 
Endogenous sex hormones during menopause. Due to the hormonal changes 
during menopause, women typically lose their resistance to CVD. Declining estrogen 
concentrations and increasing androgenic effects of progesterone have been implicated in 
altering lipid profiles. The net result of these modifications in lipid concentrations for 
postmenopausal women is an adverse change in the ratio ofHDL-C/LDL-C and an 
associated increase of risk of CAD (Khaw 1992; Tremollieres et al. 1999). Throughout 
menopause, 17 P-estradiol, the predominant form of estrogen in premenopausal women, 
decreases considerably; the major drop occurs in the perimenopausal and immediate 
postmenopausal periods (Cauley et al. 1989). The major source of estrogens in 
postmenopausal women is the conversion of androgen precursors (Khaw 1992) to estrone. 
Lipid changes closely correlate with perimenopausal changes of decreased estrogen and 
increased gonadotropins (Gaspard et al. 1995). 
Before menopause, estrogen is present in high enough concentrations to exert a 
protective role against atherogenic lipoproteins. The antiatherogenic effects of estrogen 
include increasing/maintaining HDL-C and apolipoproteins A-I and A-II, but decreasing TC, 
LDL-C, and apolipoprotein B (Bonithon-Kopp et al. 1990). Premenopausal endogenous 
estrogen also maintains low TG concentrations; lack of estrogen during menopause is 
associated with an increase in TG (Jensen et al. 1990). 
The mechanism of estrogen's protective effect is uncertain, but may be at the level of 
regulating enzyme concentrations relevant to lipid metabolism. Estrogen reduces hepatic 
lipase, which reduces TG and phospholipid hydrolysis and inhibits HDL-C catabolism, 
thereby increasing HDL-C concentrations. However, declining estrogen status due to natural 
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menopause has not been shown necessarily to promote the usual decrease in HDL-C (Lobo 
1990). Some researchers have reported that HDL-C concentrations will plateau and/or 
decrease after menopause due to decreased hepatic production (Sullivan 1996; Nasr and 
Breckwoldt 1998). However, other researches have found that overall concentration ofHDL-
C may not change because a decline in HDL2 is followed by an increase in HDL3 (Matthews 
et al. 1994). Estrogen also affects lipid metabolism by influencing the concentration of 
lipoprotein lipase. As estrogen decreases during menopause, lipoprotein lipase activity is 
enhanced, thereby increasing the plasma concentration ofLDL-C (Wakatsuki and Sagara 
1995). Estrogen also has a cardioprotective effect by stimulating the synthesis ofLDL 
receptors in vitro (Streicher et al. 1998), which would result in increased uptake ofLDL-C 
and chylomicron remnants. Thus, if estrogen is deficient, as occurs during menopause, LDL-
C rises presumably due to decreased LDL receptor activity (Abbey et al. 1999). 
Estrogen affects all stages of the atherosclerotic process. In the early phases, estrogen 
attenuates the buildup of atheromatous material in arterial walls and prevents the oxidation of 
LDL, a critical step in atherogenesis (Sullivan 1996; Young and Parthasarathy 1994). The 
antioxidant effect of estrogen will be discussed in a subsequent section. The antiatherogenic 
effect of estrogen has been documented at the molecular, cellular, tissue, and organ level. 
Exogenous sex hormones during menopause. The previous section illustrates the 
cardioprotective effects of endogenous estrogen. Estrogen replacement therapy has been 
shown to prevent the increased risk in CVD during menopause due to declining endogenous 
estrogen. A meta-analysis of observational studies using ERT shows a 44 to 50 percent 
reduction in overall risk for CVD, thus having a significant benefit in reducing total CVD 
mortality (Sullivan 1996). The role of estrogen in reducing CVD risk has been attributed to 
its effect on lipids, but lipid-related changes account for only 25 to 50 percent of CVD risk 
reduction (Nasr and Breckwoldt 1998). Additional mechanisms are likely related to estrogen 
as an antioxidant and anticoagulant. 
Overall, studies show that estrogens favorably alter the lipid profile, with effects 
being both dose- and structure-dependent (Nasr and Breckwoldt 1998). With estrogen use, 
HDL-C concentrations may increase by 20 percent and LDL-C may decrease similarly 
(Samaan and Crawford 1995). Synthetic estrogens, such as ethinyl estradiol and 
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diethylstilbestrol, have the most potent effects, whereas natural estrogens, such as estradiol, 
estrone, and conjugated equine estrogens, have less marked effects. Routes of estrogen 
delivery, such as oral, transdermal, or subdermal, do not seem to change the lipid-lowering 
ability of estrogen, if sufficient dosages and time are allowed (Lobo 1990). The 
administration of estrogen decreases the deposition of cholesterol and the overall size of the 
plaque in the arterial wall, as evidenced by animal studies (Adams et al. 1990; Hanke et al. 
1996). More LDL are converted into large VLDL during oral estrogen administration due to 
its stimulatory effect on hepatic LDL receptors. A significant increase in TG, HDL-C, and 
apolipoprotein A-I concentrations occurs along with a significant decrease in LDL-C. These 
changes are beneficial except for the increase in TG; however, the significance of this 
increase is questionable, since an increased output oflarge, TG-rich VLDL also occurs with 
ERT (Nasr and Breckwoldt 1998). In contrast, transdermal ERT does not increase hepatic 
production of TG or VLDL, but actually lowers TG and VLDL concentrations while 
favorably altering the lipid profile, although to a lesser degree (Crook and Stevenson 1996). 
The combination of estrogen and progestins is commonly recommended for 
postmenopausal women with intact uteri. However, the positive alteration in the lipid profile 
due to estrogen alone cannot be considered without recognizing the risks of this drug therapy. 
The risk of endometrial cancer is attenuated by the addition of progestins, whereas the risk of 
gallbladder disease and venous thromboembolic disease remains elevated (Barrett-Connor 
1999). Progestins counter the effects of estrogen due to their androgenic action, thus having 
an adverse effect on the lipid profile by increasing LDL-C and attenuating the increase in 
HDL-C (Goh et al. 1995). Depending upon the androgenic strength of the progestin, the 
positive effects of estrogen may not be completely abolished (Samaan and Crawford 1995). 
Several studies conclude, that despite the addition ofprogestins, HRT maintains most of the 
beneficial effects on lipids/lipoproteins, but attenuates the unfavorable effect of oral estrogen 
on total TG (Speroff et al. 1996; PEPI 1995). Translating this to disease risk, women at risk 
of developing_ CAD are more protected by ERT than HRT, assuming that progestins lessen 
estrogen's cardioprotective effect (Chow 1995). 
Soy protein with isoflavones. A meta-analysis documents the association of soy 
protein intake and lower risk for CHD in humans (Anderson et al. 1995). However, soy 
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protein has been known to retard the progression of atherosclerosis for more than 50 years 
(Clarkson et al. 1998). The cardioprotective effect of soy protein is evident when comparing 
data from Asian countries, where soy consumption is high and CHD rates are lower than in 
Western countries, where soy consumption is low and CHD rates are higher (Coward et al. 
1993; Terpstra et al. 1983). Many mechanisms have been proposed to account for the 
cholesterol-lowering effect of soy protein. One mechanism may be that soy up-regulates the 
LDL receptor, thereby increasing LDL turnover (Samman et al. 1990). Another proposed 
mechanism for the cholesterol-lowering effect is that soy protein inhibits the absorption of 
dietary cholesterol and the intestinal reabsorption of bile acids, thereby lowering circulating 
cholesterol. An additional purported mechanism is that soy protein influences various aspects 
of the endocrine system (Potter 1998). For example, current evidence suggests that dietary 
soy protein increases plasma thyroxine concentrations; therefore, increased thryoxine 
concentrations result in increased bile acid synthesis, increased fecal bile acid excretion, and 
increased hepatic clearance ofLDL and VLDL (Forsythe Ill 1995). Soy protein is being 
investigated to identify the fraction primarily responsible for its cholesterol-lowering effect 
Isoflavones, particularly genistein and daidzein, are hypothesized to lower TC and LDL-C 
because of their structural similarity to estradiol (Markiewicz et al. 1993). Isoflavones bind to 
and activate estrogen receptors, particularly the type 2, in target tissues. However, 
isoflavones exert a much less potent estrogenic effect due to their lower relative molar 
binding affinities than estrogens (Samman et al. 1990). In women after menopause, LDL-C 
concentrations are reduced by up to 19 percent in estrogen users (Samaan and Crawford 
1995) compared to a reduction of up to 7 percent with dietary intake of soy (Potter et al. 
1998; Washburn et al. 1999). 
Characteristics and Factors Affecting Coagulation/Fibrinolytic Factors 
and Oxidative Balance 
Coagulation and fibrinolytic factors: Interrelationships; menopause, estrogen/hormone 
replacement therapy, and soy 
Kelleher (1992) concludes that several coagulation factors are directly associated with 
the incidence of CVD. Thrombotic response after an atherosclerotic plaque rupture and/or 
erosion is influenced by many factors, most notably the reactivity of coagulation factors and 
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the effectiveness of protective fibrinolysis (Rosenson and Lowe 1998). Figure 1 displays the 
interrelationship between coagulation and fibrinolysis. To understand how coagulation 
mechanisms work, both extrinsic and intrinsic pathways will be closely examined with an 
emphasis on factor VII and fibrinogen; fibrinolysis will focus on P AI-1 and Lp(a). Table 2 
lists the reference ranges for the coagulation/fibrinolytic factors in this thesis. The influence 
of menopause, ERT/HRT~ and soy with isoflavones on both coagulation and fibrinolytic 
factors will also be discussed. 
Coagulation/fibrinolysis 
The enzymatic products of the coagulation cascade from one reaction initiate the 
subsequent reaction. The cascade reactions are ordered and controlled due to the high 
sensitivity of the coagulation enzymes and by positive/negative feedback systems. This 
process is thought to be autocatalytic and self-limiting (van Dam-Mioras and Muller 1986). 
Extrinsic coagulation pathway. The extrinsic coagulation pathway is triggered by 
tissue damage or injury to the vasculature. Factor VII is the first enzyme in the extrinsic 
coagulation pathway; however, factor VII alone has limited ability to induce clotting. To 
exert its clotting activity, factor VII must bind with tissue factor, a cell surface glycoprotein 
expressed by endothelial cells and macrophages in atherosclerotic plaque. Tissue factor is the 
primary initiator of this pathway by serving as the cellular receptor for factor VII, as well as 
the cofactor for factor VII activation. Activated factor VII then forms a complex with tissue 
factor to initiate the blood coagulation process (Kalafatis et al. 1997). From this point, the 
extrinsic pathway merges with the intrinsic pathway to complete the final processes of 
coagulation. Tissue factor pathway inhibitor, a serine protease inhibitor, counterbalances the 
extrinsic coagulation activation pathway and is transported by LDL-C, Lp(a), and HDL-C. 
This inhibitor binds to factor VII activity-tissue factor complex and to activated factor X in 
the intrinsic pathway, preventing the coagulation cascade from continuing (Rosenson and 
Lowe 1998). 
Factor VII is one of the major vitamin K-dependent prothrombic factors, but 
primarily exists as a zymogen, an inert form of the enzyme. The zymogen form can be 
quantified by measuring the antigen concentration. The antigen of factor VII will reflect the 
zymogen's physical presence, but does not determine its functional ability. Once activated, 
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Figure 1. Interrelationship between the coagulation and fibrinolytic pathways. 
(Adapted from Rosenson and Lowe 1998; van Dam-Mieras and Muller 1986) 
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Table 2. Reference ranges for coagulation/fibrinolytic factors 
Coagulation factors 
FactorVII1 
Fibrinogen2 
Fibrinolytic factors 
Plasminogen activator 
inhibitor -1 1 
Lipoprotein( a )1 
1 From DeMott 1996 
2 · From Young 1998 
Present reference range 
and units 
50-150 % 
200 - 400 mg/dL 
0 - 15,000 units/L 
10-30 mg/dL 
SI reference range 
and units 
50-150 % 
2.0-4.0 g/L 
0 - 250 µkat/L 
17.2- 51.7 nmol/L 
this factor is referred to as factor Vlla and is a plasma serine proteinase responsible for 
initiating clotting. Only one percent of factor VII is activated and factor VIIa concentrations 
can be assessed separately from the zymogen form. A combined measure of the zymogen and 
preformed activity is termed factor VII coagulant activity (Morrissey 1996). Factor VII 
coagulant activity was identified in 1986 as a powerful predictor of ischemic events (Meade 
et al. 1986). Increased factor VII coagulant activity and factor VII antigen concentrations are 
considered CHD risk factors due to their correlation with major lipid/lipoprotein fractions, 
most notably with plasma TG since factor VII binds to apolipoprotein B containing 
lipoproteins (Rosenson and Lowe 1998). However, factor Vlla concentrations have not been 
found to be significantly related to fasting serum lipid levels, but assessment of this activated 
factor may be important in predicting risk of occlusive thrombi (Morrissey 1996). Factor VII 
concentrations have been found to be associated with other CHD risk factors, such as 
hypertriglyceridemia, hyperinsulinemia, diabetes, and high body mass index (Pearson et al 
1997). Total dietary fat intake, rather than the type of fatty acid, influences factor VII clotting 
activity by mediating the activation of the intrinsic coagulation pathway via the lipolysis of 
VLDL and chylomicrons (Kelleher 1992; Rosenson and Lowe 1998; Miller 1998). Factor 
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VII coagulant activity is also related to age; it continually increases throughout the lifespan, 
with a predominant rise in women after their fifties (Balleisen et al. 1985). 
Intrinsic coagulation pathway. In nonendothelial tissue, the glycoproteins 
prekallikrein and kallikrein initiate the intrinsic pathway by activating factor XII. Factor XII 
may activate factor VII during postprandial lipidemia. The proteolysis of factor XII activity 
results in the activation of factor XI. Factor IX is activated by both factor XI and factor VII. 
Like factor VII, factor IX is a vitamin K-dependent coagulation factor thought to be related 
to nonfasting TG and TC concentrations (Rosenson and Lowe 1998). Through the key 
formation of a complex, factor IX activity and factor VIII together activate factor X. Factor 
VII may also activate factor X. Factor X, coupled with factor V, then activates the reaction of 
prothrombin to thrombin. Thrombin, a serine protease, is then responsibie for the conversion 
of fibrinogen to fibrin, promoting formation of the fibrin meshwork. 
Fibrinogen is synthesized by hepatocytes and i's an acute phase protein triggered by 
interleukin-6 during inflammation (Herrick et al. 1999). This protein functions to clot the 
blood and thereby forms a barrier against blood leakage through the damaged blood vessel 
wall. A fibrin clot acts as a network retaining blood cells and certain plasma proteins. 
Fibrinogen also serves to support fibroblast proliferation during wound healing and may be 
involved in defense mechanisms. Fibrinogen is a major determinant of blood and plasma 
viscosity; concentrations greater than 400 mg/dl have been linked to cerebrovascular disease 
(Kelleher 1992). Elevated concentrations of fibrinogen are also used to independently predict 
an increased risk of atherosclerotic CVD, since fibrinogen exists as a surface component of 
both fatty streaks and atherosclerotic plaque. Once in plaque, fibrinogen may be converted to 
fibrin by cells within the arterial wall. Fibrin then provides an absorptive surface area for the 
atherogenic lipoproteins LDL and Lp(a) to localize within the plaque. Degradation of 
fibrinogen occurs as well during the process of plaque formation, and evokes cell 
disorganization and migration within the endothelium (Rabbani and Loscalzo 1994; 
Warkentin 1995). Factors directly associated with higher fibrinogen concentrations are 
female sex, black race, low socioeconomic status, age, menopause, obesity, a carbohydrate-
rich diet, diabetes, cigarette smoking, inflammation, infection, elevated systolic blood 
pressure, TC, LDL-C, Lp(a), and/or serum insulin. In regions with high CVD rates and cold 
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ambient temperatures, fibrinogen concentrations are also higher. Lower fibrinogen 
concentrations are associated with male sex, adult height, HDL-C, testosterone concentration, 
postmenopausal estrogens, physical activity, moderate alcohol consumption, and/or a diet 
rich in polyunsaturated fat (Pearson et al. 1997). 
Fibrinolytic pathway. This pathway is capable of dissolving blood clots and 
includes the components plasminogen activators, plasminogen/plasmin, and fibrinolytic 
inhibitors. Plasminogen activators, primarily tissue plasminogen activator, convert the liver-
derived inactive plasminogen to plasmin. Plasmin functions to degrade fibrinogen/fibrin by 
proteolysis. Fibrinolytic inhibitors include PAI-I and Lp(a) (Dobroski and Loscalzo 1996). 
The fibrinolytic pathway is regulated by the balance between tissue plasminogen activator 
and its main inhibitor PAI-I. 
Plasminogen activator inhibitor-I, a serine protease inhibitor, acts specifically on 
tissue plasminogen activator to indirectly impair fibrinolysis through the conversion of 
plasminogen to plasmin. Endothelial cells produce PAI-I in response to the daily circadian 
fluctuation of net fibrinolytic activity (Kadish 1995). Elevated concentrations of PAI- I are 
associated with increased VLDL and TG concentrations, possibly linking PAI-I to 
atherogenesis (Dobroski and Loscalzo 1996). Elevated PAI-I concentrations have been noted 
in patients with preexisting CAD and in survivors of myocardial infarction who are less than 
45 years of age (Rosenson and Lowe 1998). Although concentrations of PAI-I are directly 
related to the extensiveness of atherosclerotic plaque, it is difficult to determine which is the 
predisposing factor. Obesity and associated metabolic conditions, such as hyperglycemia and 
hyperinsulinemia, also seem to be associated with elevated PAI-I concentrations (Pearson et 
al. 1997). Additional factors that influence PAI-I concentrations include gender and 
smoking, but body mass index along with TG concentrations are the strongest predictors of 
P Al- I (DeLoughery 1999). 
Lipoprotein(a) is a macromolecular complex having a cholesteryl-ester rich LDL-like 
structure. Lipoprotein(a) contains a protein moiety, which is similar to plasminogen in 
structure (Scanu 1992). Low density lipoproteins and Lp(a) have several similar physical and 
chemical properties, including a high content of cholesteryl ester, ~30 to 45% by weight. Tue 
properties that distinguish LDL from Lp(a) are its larger particle size (28 nm), higher 
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molecular weight, more buoyant density (1.050-1.100 g/ml), higher content of protein (30% 
by weight), and higher carbohydrate content (Chapman et al. 1994). Lipoprotein(a) synthesis 
occurs in the liver at a rate speculated to be dependent upon the flux of cholesterol and TG 
into the hepatocyte (Scanu 1992). Clearance ofLp(a) from the circulation depends upon 
whether the particle exhibits low or high molecular weight.Low molecular weight Lp(a) 
have been shown to be preferentially taken up by the LDL receptor, whereas the high 
molecular weight Lp(a) are thought to be taken up by the LDL receptor-related protein/alpha 
2-macroglobulin receptor (Marz et al. 1993). However, Lp(a) catabolism using both cell 
culture systems and in vivo turnover studies has not invariably implicated the LDL receptor 
in Lp(a) degradation (Scanu 1992). 
Although "normal" concentrations of Lp(a) have yet to be established, a typical upper 
limit in the literature is 30 mg/dl (Bartens and Wanner 1994). Circulating concentrations are 
influenced largely by heritability (Dahlen 1994), but also by sex hormones, resulting in . 
decreases with androgen and estrogen administration and increases with growth hormone 
administration (Berglund 1995). Disease states, such as diabetes, hyperlipidemia, and kidney 
disease, typically increase Lp(a) concentrations (Bartens and Wanner 1994). Tamoxifen, 
niacin, gemfibrozil, omega-3 fatty acids, N-acetylation, prednisone, and neomycin are 
considered Lp(a) lowering agents (Hajjar and Nachman 1996). A physiological function of 
Lp(a) has not been defined, although evidence indicates that Lp(a) is atherosclerotic.and 
thrombotic in nature. Lipoprotein(a) transverses the endothelium, permitting the particle to 
accumulate in the extracellular space. 
The following series of events may be responsible for the atherosclerotic potential of 
Lp(a). Lipoprotein(a) leaves the bloodstream and accumulates in the intimal space of the 
arterial wall. Chemical modification ofLp(a) occurs due to interaction with oxygen-free 
radicals, proteoglycans, glycosaminoglycans, or other matrix components, such as fibrin. The 
oxidative behavior ofLp(a) is determined by the nature and proportion of fatty acids 
associated with cholesteryl esters, phospholipids, and TG, in addition to the antioxidant 
content. Chemically modified Lp(a) is taken up by the scavenger receptor of resident 
macrophages which is then transformed into foam cells (Scanu 1992). This last event is an 
initiating step in the atherosclerotic process. Elevated LDL-C may in fact be obligatory for 
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the atherogenicity ofLp(a). However, the relative risk of elevated Lp(a) is significantly 
increased in patients who also have high LDL-C (Bartens and Wanner 1994) concentrations. 
Overall, Lp(a) favors cholesterol deposition in the developing plaque (Chapman et al. 1994). 
Lipoprotein(a) exerts a prothrombotic effect through its role in the fibrinolytic 
system. As previously mentioned, Lp(a) is similar in structure to plasminogen and interacts 
with cellular components and protein cofactors of fibrinolysis (Scanu 1992). Specifically, 
Lp(a) inhibits tissue plasminogen activator activity, the primary activator of plasmin 
formation. Lipoprotein(a) also prevents plasminogen from binding to the endothelium, thus 
impairing endothelial cell-surface-mediated fibrinolysis (Dobroski and Loscalzo 1996). 
Overall, Lp(a) favors the development of blood clots. 
Menopause, estrogen/hormone replacement therapy, and soy 
Endogenous sex hormones during menopause. Variations of circulating 
endogenous estrogen in premenopausal women during the follicular and luteal phases of 
menstruation have not been associated with significant fluctuations in Lp(a) concentrations 
(Haines et al. 1996), although fibrinolysis may be reduced during the luteal phase. Pregnancy 
has been associated with an increase in Lp(a), fibrinogen, and factor VII concentrations 
(Meilhan et al. 1992). Endogenous androgens are also known to favorably affect fibrinolytic 
activity (Winkler 1996). 
Research suggests that hemostatic changes contribute to the increased risk of CVD 
after menopause (Meilhan et al.1992). Loss of estrogen is accompanied by large increases in 
factor VII coagulant activity, plasma fibrinogen, and in P AI-1 (Winkler 1996). 
Postmenopausal women tend to have a 6 to 10 percent higher concentration of factor VII 
coagulant activity and fibrinogen when compared to premenopausal women of the same age 
(Meade et al. 1983). The type of menopause also influences the extent of the increase in these 
factors, with greater increases in factor VII coagulant activity and fibrinogen occurring in 
women who have experienced natural versus artificial menopause (Meade et al. 1990). 
Exogenous sex hormones during menopause. The effect of exogenous sex 
hormones on coagulation/fibrinolysis is dose- and structure-dependent. Synthetic estrogen in 
the form of oral contraceptives has been associated with an increase in factor VII 
concentrations, but consistent effects have not been reported for Lp(a) (Meilhan et al. 1992). 
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Estrogen in the form of 17 ~-estradiol or ERT has been shown to decrease Lp(a) 
concentrations by 24 percent, but this drop is not maintained after 12 weeks of treatment 
(Shewmon et al. 1994). Factor VII has also been shown to increase primarily with synthetic 
oral estrogens, whereas transdermal estrogens have not been shown to significantly alter 
coagulation/fibrinolytic factors, likely due to their lack of first pass through the liver. Overall, 
chronic ERT has not been shown to improve blood flow through a main coronary artery, 
suggesting a possible lack of effect of treatment on coagulation/fibrinolytic functioning 
(Guzzo et al. 1999). With the addition of progesterone, HRT has some positive effects in 
improving fibrinolysis (Lijen and Collen 1996). After one year of cyclic or continuous HRT 
administration, Andersen et al. (1999) found a decrease in fibrinogen, tissue plasminogen 
activator, PAI-1, and Lp(a), but an increase in factor VII coagulant activity. However, this 
increase in factor VII with HRT js riot as dramatic as the increase noted with ERT. Wright et 
al. ( 1997) reported significantly higher mean factor VII coagulant activity concentrations in 
ERT (144%) compared with HRT users (116%). Those postmenopausal women not taking 
any forin of replacement hormones had an intermediate increase in factor VII coagulant 
activity (130%). It is hypothesized that estrogen may increase factor VII concentrations 
through increased activation while the addition of progesterone abolishes this rise (Wright et 
al. 1999). Overall, the implications of increases in factor VII with ERT or decreases with 
HRT are unclear. Estelles et al. (1999) found decreases in PAI-1 along with decreases in the 
inhibition ofplasmin generation due to a decrease in Lp(a) concentrations with HRT 
administration. However, based on all available studies to date, it seems that there is an 
overall shift toward a procoagulant state during ERTIHRT administration. This may explain 
the increased risk ofthromboembolism (van Baal et al. 2000) with hormone therapy._ 
Soy protein "'.ith isoflavones. Soy protein, particularly the isoflavone genistein, has 
been shown to interfere with platelet aggregation and thrombin action (Wilcox and 
Blumenthal 1995). Therefore, genistein may reduce thrombosis associated with 
atherosclerosis. Studies have shown that genistein hinders thrombosis by inhibiting tyrosine 
kinase activity (Ozaki et al. 1993), thus preventing thrombin-induced platelet activation and 
aggregation (Sargeant et al. 1993; Asahi et al. 1992). These studies focused on in vitro 
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mechanisms, whereas further studies to examine the in vivo affects of soy with isoflavones 
on the coagulation system should be conducted. 
Oxidative balance: Mechanisms; menopause, estrogen/hormone replacement therapy, 
and soy 
Oxidative stress may be defined as a disturbance in the equilibrium status of 
prooxidant/antioxidant systems in intact cells. A balance between the generation of 
prooxidant and the detoxification by antioxidants occurs during normal production of 
radical species. If dietary antioxidants are depleted or excess radicals are formed due to 
disease, oxidative stress may occur causing damage to carbohydrates, nucleic acids, 
proteins, and lipids. Oxidative stress is currently being studied for its role in the 
development and progression of human disease, including atherosclerotic CVD. This 
section will discuss the types of radical species and their actions on macromolecules. The 
antioxidant defense systems that include enzymes and vitamins are reviewed next. The 
antioxidant properties of estrogen and the changes during menopause are reviewed in 
relation to CVD risk. Soy and their isoflavones with their antioxidant effect in preventing 
lipid peroxidation conclude this section. 
Radical species 
A radical species is defined as any atom capable of independent existence that 
contains one or more orbital electrons with unpaired spin states. Radicals may be very 
reactive with other biomolecules or may be relatively inert. Radicals may be composed of 
part of a large biomolecule, such as carbohydrate or lipid, or a small molecule, such as 
oxygen. Reactive molecules that contribute to the oxidative stress of aerobic cells include 
oxygen and its radical derivatives, transition metals such as iron and copper, and nitrogen 
radicals (Cheeseman and Slater 1993). Table 3 lists reactive species as discussed in the text. 
Radicals of oxygen. Radicals of oxygen are formed by one-electron reductions 
starting with atmospheric oxygen. Atmospheric oxygen has orbital electrons with the same 
spin states; thus, atmospheric oxygen is not very reactive with biomolecules. Oxidation of 
atmospheric oxygen by cellular processes, including mitochondrial electron transport 
systems, produces the superoxide anion. Additional sources of the superoxide anion may be 
from the action of phagocytic cells as they destroy foreign organisms or xanthine 
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dehydrogenase/oxidase reactions. The superoxide anion is not very reactive alone, but may 
combine with other reactive species to yield a highly reactive radical. The superoxide ion is 
involved in both the initiation and termination of lipid peroxidation (McCord 1993). The fate 
of the superoxide anion involves the rapid conversion to hydrogen peroxide, the next one-
electron reduction in line for the oxygen species. Hydrogen peroxide is considered a 
nonradical oxygen species since it has no unpaired electrons. Sources of hydrogen peroxide 
are similar to that of the superoxide anion. Metabolic roles of hydrogen peroxide include the 
iodination of thyroid hormones via the peroxidase enzyme in the thyroid gland and the 
expression of certain genes that play a role in immune function. Further reduction of 
hydrogen peroxide yields the hydroxyl radical. This radical is highly reactive with all 
biomolecules and is considered the most toxic of the partially reduced oxygen species, 
causing structural damage to macromolecules and breakage of DNA strands (Santanam et al. 
1998). Singlet oxygen, a second form of oxygen, is the final result of further oxidation of 
other partially reduced oxygen species. Singlet oxygen differs from atmospheric oxygen 
since its pair of electrons is not in the same spin state and therefore is more reactive 
(Cheeseman and Slater 1993). 
Table 3. Reactive speciesl 
Name 
Singlet oxygen 
Superoxide radical 
Hydrogen peroxide 
Hydroxyl radical 
Nitric oxide 
Peroxyl radical 
Perhydroxyl radical 
I From Rice-Evans and Burdon 1993 
Symbol 
H2O2 
·OH 
NO· 
ROO· 
HOO· 
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Transition metals. Transition metals interact with oxygen and its derivatives in 
reversible redox reactions to generate free radicals (Halliwell 1993). Pathological production 
of superoxide liberates iron from a bound state; unbound iron is then available to catalyze the 
Haber-Weiss reaction, which produces the hydroxyl radical. Free iron may also serve to 
initiate lipid peroxidation (McCord 1993). Reduced iron and copper are more reactive with 
hydrogen peroxide than the oxidized forms of these metals (Cheeseman and Slater 1993). 
3+ .- 2+ Fe + 02 Fe + 02 
.- + 202 + 2H H2O2 + 02 
Fe2+ + H2O2 .~ "OH+ OH-+ Fe3+ 
Nitric oxide radicals. Nitrogen radicals are in the form of nitric oxide (NO) and are 
generated from the oxidation of arginine via nitric oxide synthase. Several compounds, such 
as calcium and calmodulin, along with the process of phosphorylation, regulate NO synthesis 
(Bredt and Snyder 1994). Nitric oxide functions both as a prooxidant and antioxidant. Nitric 
oxide serves as a prooxidant by inhibiting peroxidase enzymes, which serve as potential 
initiators of lipid peroxidation. Nitric oxide also serves as an antioxidant by inhibiting lipid 
peroxidation through its action as a scavenger for lipid peroxyl radicals (Hogg and 
Kalyanaraman 1999). Another role of NO that may attenuate CVD risk is due to inhibition of 
platelet aggregation and hence regulation of the vascular system (Bredt and Snyder 1994). 
Nitric oxide functions as a biological signal in smooth muscle relaxation, neurotransmission, 
and immune regulation. Some of the prooxidant biological effects may be due to NO 
combining with another reactive molecule, such as superoxide anion, to produce significant 
amounts of peroxynitrite (ONOO), which in turn mediates the oxidation ofboth non-protein 
and protein sulfhydryls (Radi et al. 1991). 
02.- + NO ONOO-
ONOO- + H ONOOH 
ONOOH OH + NO2 
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Radical species and macronutrients. The overall reactivity of free radicals depends 
on the type of radical and what challenge is presented to the radical. Two radical species may 
react to join their unpaired electrons to form a covalentbond, the result of which is a more 
reactive molecule. When a free radical reacts with a nonradical, a new free radical forms, 
causing the start of a chain reaction. Most biological reactions are nonradical, so interaction 
with a radical such as the hydroxyl radical can result in much damage if antioxidant defense 
systems are suppressed (Halliwell 1999). Radical species especially may have detrimental 
effects on macromolecules, possibly leading to disease states. 
When carbohydrates react with free radicals, a hydrogen atom is removed from one 
carbon atom leaving a carbon-centered radical. The loss of hydrogen atoms causes molecules 
to lose their structure and function. Hyaluronic acid, a polysaccharide, is an example of such 
a molecule affected by radical action on a carbohydrate. Hyaluronic acid is degraded by the 
superoxide anion-generating systems resulting in free radical production. Changes in the 
viscosity of hyaluronic acid and the build-up of radicals in the synovial fluid surrounding the 
joints can induce inflammation (Strukov 1983). This process accounts for a decrease in 
synovial fluid and may be linked to rheumatoid arthritis. 
Nucleic acids undergo base modifications when reacting with oxidizing radical 
species near their vicinity. Free radical species produced from the reaction of free radicals 
with amino acids or other organic molecules can damage DNA. Hydroxyl radicals in 
particular react with DNA to produce carbon-centered radicals that can then add oxygen to 
form peroxyl radicals. These modifications can lead to cell death, reproductive death, 
mutation, and carcinogenic transformation (Bohr et al. 1998). 
Proteins are not as prone to damage as are lipids. Protein reacting with a radical 
species causes fragmentation due to many reactive sites on the protein molecule. Damage to 
a cell is only significant if the fragments are allowed to accumulate in the cell or if certain 
sites are affected (Cheeseman and Slater 1993). Proteins with metal-binding sites are 
especially susceptible to oxidative stress, as these sites interact with other metals . 
. Modification of proteins can signal them to be degraded or possibly protect them, depending 
on which amino acid is affected. Degradation by the oxidation of a thiol group can lead to the 
loss of enzyme function, of ion transport, and/or of contractile function of proteins. The 
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protective nature of the amino acids cysteine and methionine is due to reverse Inodification to 
different forms of amino acids, which eventually causes the detoxification of oxidant species 
(Thomas 1999). 
Lipids are the most susceptible class of biomolecules to attack by free radicals. The 
chain reaction process caused by the oxidizing radicals is called lipid peroxidation, or the 
oxidative destruction of polyunsaturated fatty acids. Table 4 delineates the steps of lipid 
peroxidation. The types of lipids and lipoproteins most affected in cells are those involved in 
membrane structure. Once these lipids and lipoproteins are damaged, serious impairment of . 
cell function occurs. A more detailed list of consequences of lipid peroxidation is 
summarized in Table 5. 
Table 4. Steps oflipid peroxidation1 
Step Reaction 
Initiation ljpid + R/OH · lipid · 
Propagation lipid·+ 0 2 lipid-00 · 
lipid-00 · + lipid lipid-OOH + lipid · 
Termination lipid·+ lipid · lipid-lipid 
lipid-00 · + lipid · lipid-00-lipid 
Scavenging lipid · + vitamin E lipid + vitamin E · 
I From Thomas 1999 
Table 5. Consequences of lipid peroxidationl 
Loss/degradation of polyunsaturated fatty acids 
Altered membrane permeability and membrane-associated enzymes 
Altered ion transport 
Generation of cytotoxic metabolites of lipid hydroperoxides 
Release of material from subcellular compartments (e.g. lysosomal enzymes) 
I From Rice-Evans and Burdon 1993 
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Oxidized LDL is considered a risk factor for CVD (Berliner and Heinecke 1996; 
Regnstrom et al. 1994), and is a result oflipid peroxidation via free radicals. The first 
reaction of lipid peroxidation is termed initiation, involving the removal of a hydrogen atom 
from a polyunsaturated fatty acid by a free radical. A carbon-centered lipid radical results, 
reacting with oxygen in the next reaction to yield a lipid peroxyl radical. Chain propagation 
begins by the peroxyl radical extracting a hydrogen atom from a nearby lipid, resulting in a 
lipid hydroperoxide and a new lipid radical. The rate of lipid peroxidation is dependent upon 
the presence of antioxidants and the rate of termination. Antioxidants, mainly phenolic, 
scavenge the lipid peroxyl radical to yield a phenoxyl radical with low reactivity that will not 
propagate the lipid peroxidation chain. Natural termination occurs when two lipid peroxyl 
radicals combine to form a nonradical product and oxygen (Cheeseman and Slater 1993). 
Once the oxidized LDL is formed by lipid peroxidation, it is not taken up by classical 
LDL receptors, but is instead taken up by macrophages via a scavenger receptor (Steinberg 
1996). After being deposited in arterial walls, oxidized LDL releases cytotoxic lipid 
peroxidation products resulting in damage to the endothelial cell layer. This damage invokes 
endothelial cell death, platelet aggregation, accumulation ofinflammatory cells, and 
increased infiltration ofLDL. T-lymphocytes are oxidized by oxidized LDL, which in tum 
stimulates the proliferation of smooth muscle cells. Thus, oxidized LDL plays a central role 
in atherogenesis (Jialal and Devaraj 1996). 
Lipid peroxidation also impairs the function ofHDL-C, causing it to lose its 
protective effect against elevated serum cholesterol. Oxidized HDL particles are not taken up 
by macrophages and do not lead to foam cell formation, unlike oxidized LDL. Instead, once 
HDL is modified by oxidation, this lipoprotein has an impaired ability to stimulate efflux of 
cholesterol from foam cells (Nagano et al. 1991) and extrahepatic tissues (W akatsuki et al. 
1998). 
Antioxidant defense systems 
Exposure to hydroxyl radicals is unavoidable since they are naturally made ~uring the 
splitting of oxygen and hydrogen bonds in water due to ionizing radiation from the 
environment (Santanam et al. 1998). The highly reactive hydroxyl radical interacts with all 
biological molecules and thus damage is unavoidable. Antioxidant defense systems minimize 
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the production of the hydroxyl radical and subsequent damage. Examples of antioxidant 
defense systems include enzymes, plasma proteins, and dietary intake of antioxidants 
(Thomas 1999). Total plasma or serum antioxidant levels in normal human plasma are within 
the range of 1.30 to 1.77 mM (Miller et al. 1993). Components of the various antioxidant 
defense systems are specified in Table 6. 
Table 6. Antioxidant defense systems1 
Enzymes: 
(i) superoxide dismutase - converts radicals to hydrogen peroxide 
(ii) catalase - detoxifies hydrogen peroxide 
(iii) glutathione peroxidase - detoxifies hydrogen peroxide and lipid peroxidases in 
the presence of reduced glutathione 
Plasma proteins: 
(i) ceruloplasmin - acts as an antioxidant by virtue of its ferroxidase activity 
(ii) albumin - binds metals, especially copper but also iron weakly 
· (iii) transferrin - sequesters Fe3+ rendering it unavailable for catalyzing the Haber-
-Weiss reaction, initiating lipid peroxidation 
(iv) heptoglobin/hemopexin - binds free heme 
Dietary intake: 
(i) alpha tocopherol - scavenges peroxyl radical intermediates 
(ii) ascorbic acid - water soluble antioxidant; acts synergistically with tocopherol 
(iii) beta-carotene - mechanism undefined 
1 From Rice-Evans and Burdon 1993 
Enzymes. Superoxide dismutase functions as an enzymatic antioxidant defense 
system. Superoxide dismutase is present in human cells as a copper-zinc-containing enzyme 
in the cytoplasm and as a manganese-containing enzyme in the mitochondria. Superoxide 
dismutase is responsible for minimizing intracellular superoxide radicals by converting the 
radical to hydrogen peroxide (Fridovich 1989): 
202·· + 2H+ --+- H202 + 02" 
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The concentration of intracellular superoxide dismutase must be kept in balance since too 
little may be lethal while excess may result in hydrogen peroxide toxicity. The genetic 
overexpression or therapeutic administration of superoxide dismutase may cause metabolic 
problems or exacerbate an injury, which illustrates the importance of maintaining optimal 
concentrations of this enzyme (McCord 1993). Once hydrogen peroxide is formed, catalase 
converts this toxic nonradical to water and oxygen. Catalase is a heme protein formed in 
peroxisomes of most cells or in the cytoplasm of the erythrocytes (Thomas 1999). 
Glutathione and reactive sulfur-containing proteins are also participants in the 
enzymatic antioxidant defense system. Glutathione detoxifies by reacting with harmful by-
products of aerobic life, hydrogen peroxide, and organic peroxides. Glutathione is the major 
intracellular soluble antioxidant in the cytoplasm, nuclei, and mitochondria. Enzymes 
mediate the glutathione redox cycle, which cause glutathione to cycle between a thiol form 
and an oxidized form. Glutathione peroxidase, a selenium-containing enzyme, catalyzes the 
oxidation of glutathione (GSH) by hydrogen peroxide to glutathione disulfide (GS-SG): 
2GSH + H2O2 GS-SG + 2H2O 
Other enzymes using lipid peroxides may also catalyze this oxidative reaction rather than 
using hydrogen peroxide as the oxidant, indicating that glutathione detoxifies both soluble 
and lipid peroxides: 
2GSH + LOOH GS-SG +LOH+ H2O 
To complete the cycle, glutathione disulfide is reduced to glutathione via glutathione 
reductase using NADPH as the reductant (Thomas 1999): 
GS-SG + NADPH + H+ 2GSH + NADP 
Glutathione's antioxidant effect.depends upon its cellular concentration, which may vary due 
to the extent of nutrient limitations, exercise, and oxidative stress (Meister 1988). 
Reactive protein suljhydryls participate in detoxification via the protein S-thiolation 
cycle. Protein sulfhydryls are found in soluble and membrane-bound proteins. Oxidative 
stress modifies these proteins to create mixed disulfides with attached glutathione (S-
thiolation). The sulfur atom easily loses a single electron, resulting in a sulfur radical species 
with a longer lifespan, compared to other radical species resulting from oxidative stress 
(Thomas 1999). 
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Plasma proteins. Human cells have specific enzyme antioxidant defense systems, 
whereas plasma contains little of these enzymes; thus, oxidative stress affects mostly 
lipoproteins, such as LDL. Protein constituents and other small molecules exert protective 
antioxidant properties. Important proteins that serve to sequester potentially damaging 
transition metals, such as iron and copper, are ceruloplasmin, albumin, and transferrin. If 
unbound to proteins, iron and copper can participate in generating the most reactive radical 
species, the hydroxyl radical. Heptoglobin and hemopexin proteins bind the source of iron 
that is involved in lipid peroxidation, free heme. However, it is unlikely that extracellular 
free metal ions exist under normal arterial conditions (Thomas 1999). The proteins may have 
a protective effect, particularly during pathological conditions when metal ions might be 
available (Berliner and Heinecke 1996). 
Dietary intake. Vitamins also serve as free radical scavengers within membranes 
and lipoproteins. Vitamin E ( a-tocopherol) slows the chain reaction of lipid peroxidation by 
scavenging the peroxyl radical intermediates. The resulting a-tocopherol radical is less 
reactive than peroxyl radicals and may be recycled to a-tocopherol by the action of ascorbic 
acid (Diaz et al. 1997). The antioxidant effect of ascorbic acid is also demonstrated by its 
detoxification of inhaled air pollutants (i.e., ozone, nitrogen dioxide). Ascorbic acid also has 
prooxidant effects in the presence of transition metal ions by reducing them and subsequently 
generating free radicals. However, metal ions are not readily available in vivo, and thus 
ascorbic acid exerts an overall antioxidant effect (Jacob 1999). High plasma levels of fl-
carotene have been linked to a decrease in cancer and CVD. The mechanism of P-carotene as 
an antioxidant is in question, since antioxidant effects have been documented in vitro, 
whereas the mechanism of P-carotene's effect in vivo remains unknown. All of these dietary 
constituents have antioxidant characteristics in vitro and in vivo by reducing the oxidative 
susceptibility ofLDL (Diaz et al. 1997; Jialal and Fuller 1995). 
Menopause, estrogen/hormone replacement therapy, and soy 
Endogenous sex hormones during menopause. Estrogens produce both prooxidant 
and antioxidant effects, with potency being structure-dependent (Klein and Berlin 1997). The 
prooxidant effects of estrogens occur when they are converted to catecholestrogens upon 
oxidation during the redox cycle. Reactive oxygen species result from this cycle, which may 
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induce damage to DNA, proteins, and lipids. One condition when an antioxidant, such as 
estrogen, acts as a prooxidant is during peroxidase-catalyzed oxidation reactions. During this 
type of reaction, antioxidants form phenoxy radicals to promote oxidation by interaction with 
either apolipoprotein molecules ofLDL or directly with lipids. Once oxidized, LDL may be 
rapidly cleared from the circulation by the liver. This process may aid in the clearance of 
LDL by the liver. Hence, estrogens, in the case of peroxidase-catalyzed oxidation reactions, 
may be antiatherogenic since the oxidation ofLDL is promoted (Nathan and Chaudhuri 
1998). 
Estrogens may exert antioxidant effects by participating in the iron redox cycle. 
Estrogens alter iron chelation and prevent iron from inducing lipid peroxidation (Schwenke 
1998). Estrogens also act on genes with response elements for antioxidants. By this 
mechanism, estrogens may inhibit expression of proteins involved in atherogenesis (Nathan 
and Chaudhuri 1998). Overall, in vivo physiological concentrations of estrogen may have 
modest antioxidant activity, whereas prooxidant activity is unlikely (Schwenke 1998). 
Shwaery et al. (1998) speculate that 17 -~-estradiol in particular is responsible for the 
majority of the antioxidant protective effect in premenopausal women. 
Exogenous sex hormones during menopause. The oxidation of HDL particles has 
been shown to decrease with estrogen in vitro (Wakatsuki et al. 1997); however, the 
cardioprotective effect of exogenous administration of ERT/HRT has been mainly attributed 
to the inhibition of peroxidation, which slows the uptake of oxidized LDL by macrophages 
(Maziere et al. 1991 ). Endogenous metabolites of estradiol have been found to be more 
potent inhibitors of LDL oxidation than both exogenous estradiol and vitamin E combined in 
vitro (Seeger et al. 1998). However, equine estrogens are found to be more potent 
antioxidants than human estrogens and effectively inhibit fatty acid and cholesterol oxidation 
in vitro (Nathan and Chaudhuri 1998). 
In vitro administration of supraphysiological concentrations of 17 B-estradiol have an 
inhibitory effect on both copper and cell-mediated oxidation ofLDL (Maziere et al. 1991; 
Huber et al. 1990). In vivo studies with postmenopausal women involving various types of 
estrogen treatment have shown mixed results. Sack et al. (1994) found that administration of 
17 B-estradiol at physiological levels has an antioxidant effect of inhibiting the oxidation of 
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LDL. However, McManus et al. (1997) found that transdermal estradiol, oral estradiol 
valerate, and conjugated equine estrogen all failed to support the antioxidant effect of 
estrogens. Explanations for this lack of effect in vivo include: 1) concentrations of estrogens 
necessary for reduced lipoprotein oxidation must be 104 to 106 times greater than that found 
in the plasma of premenopausal women, or as a result of HRT in postmenopausal women 
and/or 2) estrogens also increase the proportion of small, dense LDL particles, which would 
increase their susceptibility to oxidation and increase their rate of uptake, with no net change 
in oxidized LDL concentration. It is unclear whether estrogens are in fact incorporated into 
LDL particles deposited in the arterial wall and in tum affect production of free radicals and 
oxidative modification ofLDL. More studies are needed to determine the dose of estrogen 
needed to exert an antioxidant effect and the mechanism of estrogen's purported antioxidant 
activity (McManus et al. 1997). 
Soy protein with isoflavones. Flavonoids, particularly isoflavones, exert antioxidant 
properties through reversible and irreversible electron transfer reactions. The antioxidant 
capacity of isoflavones is due to their ability to donate hydrogen atoms and/or electrons from 
their hydroxyl groups to free radicals (Mitchell et al. 1998). The extent of flavonoid 
antioxidant activity depends on the reduction potentials of their radicals and their availability 
at the site of pathological oxidative processes. Flavonoids have been specifically studied in 
relation to their inactivation of the superoxide radical. Through this mechanism, flavonoids 
inhibit lipid peroxidation and singlet oxygen quenching that in tum may cause damage to 
DNA, alter respiration, and damage the endothelium (Jovanovic et al.1998). The major 
aglycone forms of isoflavones, genistein, daidzein, and glycitein, are known to exert 
antioxidant effects due to their unique structures. However, the antioxidant activity does not 
seem to be dictated by form, since activity of the aglycone forms of the isoflavones are 
comparable or superior to their parent forms (genistin, daidzin, and glycitin) (Arora et al. 
1998). Genistein is the most potent antioxidant among the isoflavones and is approximately 
40% more powerful than daidzein due to structural differences (Rice-Evans and Miller 
1998). Genistein exhibits antioxidant properties by preventing lipid peroxidation induced by 
the iron redox cycle (Cai and Wei 1996). Kapiotis et al. (1997) found human endothelial cell-
mediated LDL oxidation in vitro to be inhibited upon incubation with genistein. 
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Summary 
In summary, dyslipidemia, .altered coagulatfon/fibrinolysis, and oxidative stress are 
viewed as CVD risk factors in mid-life women. Estrogen concentrations in premenopausal 
women serve to: 1) exert a beneficial effect on circulating lipids, 2) favorably alter 
coagulation/fibrinolysis, and 3) maintain oxidative balance. Declining 17 13-estradiol 
concentrations during menopause are related to adverse changes in the lipid profile, increased 
coagulation activity, and increased oxidative stress. Hormone therapy favorably alters the 
lipid profile and the balance between coagulation and fibrinolysis. However, based on 
available studies to date, there is an overall shift towards a procoagulant state with ERT, 
likely explaining the increased risk of thromboembolism. Studies have produced mixed 
results as to whether or not hormone therapy exerts an antioxidant effect on circulating 
lipids/lipoproteins. Alternatives for hormone therapy that reduce CVD risk but do not impose 
further risk, as is associated with HRT/ERT, are currently being investigated. Soy protein, 
particularly in conjunction with its isoflavones (estrogen-like compounds), has been 
documented to exert a hypocholesterolemic as well as an antioxidant effect. Genistein in 
particular induces fibrinolytic enzyme activity, thus favoring fibrinolysis. Researchers are 
currently investigating whether consumption of soy protein with isoflavones or isoflavones 
alone in peri- and postmenopausal women will have beneficial effects similar to HRT/ERT. 
More research is needed to determine if soy protein, whether or not due to its isoflavone 
content, consistently favorably alters the lipid profile, coagulation/fibrinolysis, and oxidative 
balance in normo- and hypercholesterolemic peri- and postmenopausal women. 
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CIRCULATING LIPIDS/LIPOPROTEINS AND 
COAGULATION/FIBRINOLYTIC FACTORS IN 
PERIMENOPAUSAL WOMEN TREATED WITH SOY 
PROTEIN 
A paper to be submitted to American Journal of Clinical Nutrition. 
Sarah B. Dent1, Charles T. Peterson2, Larry D. Brace3, Kathy B. Hanson1, James H. Swain1, 
Manju B. Reddy1, Jennifer G. Robinson4, D. Lee Alekel1•5 
ABSTRACT 
Background: Soy protein has been shown to favorably alter serum lipids/lipoproteins, 
thereby reducing cardiovascular disease (CVD) risk. 
Objective: The primary purpose was to determine the effect of soy protein ( 40 g/d) on 
. . 
circulating lipids/lipoproteins and coagulation/fibrinolytic factors in perimenopausal women. 
The secondary purpose was to determine the contribution of coagulation/fibrinolytic and 
other factors ( e.g., body size/composition; physical activity; blood pressure; serum estrogens, 
ferritin, iron; and dietary intake) to lipids/lipoproteins. 
Design: Subjects were randomly assigned, double-blind, to treatment: iso:flavone-rich soy 
protein (n=24), iso:flavone-poor protein (n=24), or whey protein control (n=21). We 
measured circulating lipids/lipoproteins at baseline, wk 12, and wk 24, and 
coagulation/fibrinolytic factors at baseline and wk 24. 
Results: Treatment did not alter lipids/lipoproteins or coagulation/fibrinolytic factors. Time 
had an effect on HDL cholesterol (F_:::0.0001) and triacylglycerol (P=0.024). Approximately 
43% of the variability in total cholesterol, 34% in triacylglycerol, 57% in HDL cholesterol, 
1 Department of Food Science and Human Nutrition, Human Metabolic Unit, Center for Designing 
Foods to Improve Nutrition, Iowa State University, Ames, Iowa 
2 Department of Statistics, Iowa State University, Ames, Iowa 
3 Department of Pathology, Division of Hospital Laboratories, University of Illinois at Chicago, 
Chicago, Illinois 
4 Iowa Heart Institute, Des Moines, Iowa 
5 Corresponding author 
41 
and 35% in lipoprotein(a) was accounted for by the factors examined. Lean body mass, 
serum 17 p-estradiol, and dietary factors (vitamin E, selenium, fiber, and folate) had 
beneficial effects (P<0.05), whereas plasma fibrinogen and plasminogen activator inhibitor-
1, diastolic blood pressure, body weight, and serum liver enzymes and ferritin had 
detrimental effects on lipid/lipoprotein concentrations. 
Conclusions: Isoflavone-rich or -poor soy protein had no effect on lipid/lipoprotein or 
coagulation/fibrinolytic factors, whereas the effect of time suggested that the hormonal 
milieu during the menopausal transition may have overridden any detectable treatment effect. 
The unconventional contributors to the lipid profiles identified in this study should be further 
examined as indices of CVD risk in mid-life women. 
KEY WORDS Cardiovascular disease risk, Factor VII, Fibrinogen, Isoflavones, 
Lipoprotein( a), Plasminogen activator inhibitor- I, Soy protein 
INTRODUCTION 
Perimenopause is considered a critical period in which preventive efforts to reduce 
the menopause-associated increase in cardiovascular disease (CVD) risk should be initiated 
(Matthews et al. 1994). Soy isoflavones, estrogen-like substances structurally similar to 17 P-
estradiol, have,been reported to favorably alter lipid profiles in perimenopausal women 
(Washburn et al. 1999) and postmenopausal (Potter et al. 1998) women. In contrast, other 
studies have not shown a beneficial effect of isoflavones (Hodgson et al. 1998; Simons et al. 
2000; Nestel et al. 1999) on circulating lipids and lipoproteins. Isoflavones, specifically 
genistein, also have been reported to favorably alter fibrinolysis by interfering with platelet 
aggregation and thrombin action in vitro (Wilcox and Blumenthal 1995). Yet, there are no 
published data on the effect of soy protein or its isoflavones on coagulation/fibrinolytic 
activity in mid-life women. Lipids and lipoproteins modulate the expression or function of 
coagulation and fibrinolytic factors, establishing their role in atherogenesis (Rosenson and 
Lowe 1998). Several coagulation factors are directly associated with CVD (Kelleher 1992), 
as evidenced by the reactivity of coagulation factors and the effectiveness of protective 
fibrinolysis (Rosenson and Lowe 1998) following the thrombotic response to an 
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atherosclerotic plaque rupture and/or erosion. Although studies have examined the 
relationship between lipids/lipoproteins and coagulation/fibrinolytic factors in atherogenesis, 
data are lacking in women during the very early stages of menopause. Thus, we determined 
the contribution of coagulation/fibrinolytic factors (plasma fibrinogen, plasminogen activator 
inhibitor-I [PAI-I], and factor VII antigen), along with other pertinent factors (such as body 
size and composition; physical activity; blood pressure; serum estrogens, ferritin, and iron; 
dietary intake of fat, alcohol, fiber, and antioxidants), to total cholesterol, LDL cholesterol, 
HDLcholesterol, triacylglycerol, total/HDL cholesterol, and lipoprotein(a) [Lp(a)] 
concentrations in perimenopausal women at baseline. 
SUBJECTS AND METHODS 
Research design and treatment 
This 24-wk double-blind study examined the effects of SPI+ (Protein Technologies 
International; St. Louis, MO), isoflavone-poor protein (SPI -; Protein Technologies 
International; St. Louis, MO), and whey protein ( control; Ross Laboratories; Columbus, OH) 
on circulating lipids/lipoproteins and coagulation/fibrinolytic factors in perimenopausal 
women. Each perimenopausal woman was randomly assigned to one of three treatment 
groups: SPI+ (80.4 mg/d aglycone components; n=24), SPI - (4.4 mg/d aglycone 
components; n=24), or control (n=21). The whey protein served as a control for protein, 
whereas the SPI - served as a control for soy protein. As free-living subjects, the subjects 
were asked to consume a total of 40 g protein/d provided in a jumbo muffin and as protein 
powder. The muffins were baked in the Human Metabolic Unit of the Center for Designing 
Foods to Improve Nutrition at Iowa State University. The subjects were instructed to 
consume the muffin and protein powder as a meal replacement and not as a supplement, 
since they were provided an additional ~2.09 MJ (500 kcal)/d. The subjects also received 
instruction on how to avoid other isoflavone-containing foods. A daily over-the-counter 
vitamin and mineral supplement was provided; the women were instructed to stop taking any 
of their own supplements before the study began. An informational meeting was held prior to 
baseline testing where the women were informed of their rights as volunteers in this study, 
signed consent forms, and were given a medical release form to be signed by their 
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physicians. The Iowa State University Human Subjects Review Committee (IRB# 01; 
Assurance ID# Ml361) approved this project's protocol and consent forms. Every six wks, 
the women were required to visit the Human Metabolic· Unit for testing, replenishment of 
supplies, and for submitting 24-hr urine samples. 
Subject screening, selection, and characteristics 
Subjects were recruited throughout the state of Iowa through newspaper and bulletin 
board advertisements, local television news stories, and newspaper articles. Telephone 
interviews were conducted to screen potential perimenopausal women to ensure they met our 
inclusion/exclusion criteria: experiencing ::::_10 hot flushes and/or night sweats per wk, had 
irregular menses or cessation of menses for less than one y, had one or both ovaries 
remaining, had a body mass index (BMI) (kg/m2) between 19 and 31, were willing to be 
randomly assigned to treatment, and able to participate for 24 wks. Women were excluded if 
they had a chronic disease (i.e., heart disease or osteoporosis), were taking medications 
chronically, had taken hormone replacement therapy or estrogen replacement therapy during 
the past 12 months, had a history of an eating disorder or menstrual disorder, and/or were 
excessive exercisers (>10.46 MJ [>2500 kcal] expenditure/wk). Once potential subjects 
qualified after the initial screening, blood was drawn to ensure that follicle· stimulating 
hormone concentrations were ::::_30 IU/L (Wilson et al. 1998); 22 were excluded on this basis. 
Women discontinued participation due to inability to tolerate treatment (n=6), medical 
conditions preventing continuance (n=2), death (n=l), or death in the family (n=l); we 
dropped one woman due to noncompliance. Because of our strict inclusion/exclusion criteria, 
we recruited women in four waves or cohorts, with subjects randomly assigned to treatment 
within each cohort. The cohorts began in January 1997, May 1997, September 1997, and 
March 1998. 
Data co)Jection and measurement 
Information on health and medical history and physical activity was obtained using 
interviewer-administered questionnaires. The health and medical history was used to rule out 
women with chronic or acute conditions or diseases and those who chronically used various 
. drugs (nonprescription, prescription, or illegal). The Paffenbarger Physical Activity Recall 
(Paffenbarger et al. 1978) was used to obtain information on weekly physical activity during 
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the previous year. Each recreational activity was summed to provide an estimate of weekly 
energy expenditure. Dietary intake was assessed at baseline, wk 12, and wk 24 using five-d 
food records. To assist the subjects in quantifying portion sizes, two-dimensional food 
portion visual aids (Nutritional Consulting Enterprises, Morgan/Posner, 1981; Framingham, 
MA) were provided. The food records were analyzed by trained nutrition students using the 
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Nutritionist IV computerized nutrient database program (Version 4.1, 1995; First DataBank, 
Inc., San Bruno, CA). The vitamin and mineral supplement provided to the subjects was not 
included in these analyses. 
Anthropometry data included measurement of height (using a stadiometer) and 
weight(using a balance beam scale [Health-o-meter, Inc.; Bridgeview, Illinois]). Dual-
energy x-ray absorptiometry via QDR-2000+ (Hologic, Inc.; Waltham, MA) was used to 
assess total body composition (lean and fat mass). Two researchers trained by Hologic, Inc. 
performed all scans; one of these researchers analyzed all total body scans with software 
provided by the manufacturer (Version 7.10, 1992; Waltham, MA). Trained personnel used a 
random.:digit sphygmomanometer (Marshall Electronics, Inc.; Skokie, IL) to measure resting 
blood pressure. 
Each subject collected a 24-hr urine sample in polyethylene containers the day prior 
to each visit to the Human Metabolic Unit. After the first morning's void, all urine was 
collected, including the next morning's void. Total volume was measured and recorded to the 
nearest 10 ml. Aliquots in 5 ml vials were frozen at -80°C for shipment to Fujicco Co. Ltd .. 
(Kobe, Japan), where urinary isoflavones were analyzed by reversed-phase HPLC to monitor 
compliance. 
Fasted blood was drawn in the early morning from each subject at baseline, wk 12, 
and wk 24 and serum (1000 x g for 15 min at 4°C) or plasma (1200 x g for 10 min at 4°C) 
was separated for measurement for the following blood analytes. Quest Diagnostics (St. 
Louis, MO), a certified clinical laboratory, performed the serum total cholesterol, LDL 
cholesterol, HDL cholesterol, and triacylglycerol measurements at each time point. LDL 
cholesterol concentrations were calculated using the Friedewald equation: (total cholesterol) 
- (HDL cholesterol)- (triacylglycerol/5) (Friedewald et al. 1972). Plasma Lp(a), factor VII 
antigen, and fibrinogen were analyzed under the supervision of Dr. Larry Brace in the 
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Hematology and Coagulation Laboratory at the University of Illinois at Chicago. Plasma 
Lp(a) [TintElize®Lp(a)] concentrations were measured at baseline, wk 12, and wk 24, using 
an immunoenzymetric method with affinity purified polyclonal antibodies against Lp(a), 
according to the manufacturer's (Biopool, International; Ventura, CA) guidelines. Lp(a) . 
concentrations were read using an automated microtiter plate reader (EL31 lsx, Bio-Tech 
Instruments, Inc.; Winooski, VT). The remaining coagulation/fibrinolytic factors were 
measured from baseline and wk 24 plasma samples. Factor VII antigen 
(Asserachrom®VII:Ag) concentrations were measured by an enzyme immunoassay 
procedure for the quantitative determination of factor VII by the sandwich technique 
according to the manufacturer's (Diagnostica Stago; Asinieres-Sur-Seine, France) guidelines. 
Factor VII antigen concentrations were read with the automated plate reader. A certified 
technician from Diagnostica Stago performed the analyses on factor VII coagulant activity, 
PAI-I, and fibrinogen. Plasma factor VII coagulant activity (Staclot®VIIa-rTF) was 
quantitatively determined by measuring the clotting time of plasma after exposure to 
recombinant soluble tissue factor according to the manufacturer's (Diagnostica Stago; 
Asinieres-Sur-Seine, France) guidelines. We were not able to measure factor VII coagulant 
activity in samples from the last cohort because of technical difficulties. Because PAI-I is 
cold temperature-sensitive, the plasma samples for P AI-1 were not placed on ice, but were 
centrifuged and kept at room temperature until frozen. PAI- I (Stachrom ®p AI) was 
quantitatively determined by the synthetic chromogenic substrate method according to the 
manufacturer's (Diagnostica Stago; Asinieres-Sur-Seine, France) guidelines. Fibrinogen was 
measured by a Clauss method using Diagnostica Stago equipment and reagent according to 
the manufacturer's (Diagnostica Stago; Asinieres-Sur-Seine, France) guidelines. Factor VII 
coagulant activity, PAI-1, and fibrinogen were analyzed using the STA-R automated 
coagulation analyzer (Diagnostica Stago; Asinieres-Sur-Seine, France). 
Serum ferritin was determined using an enzyme-linked immunoassay obtained from 
RAM CO Labs {Houston, TX). Quest Diagnositics (St. Louis, MO) measured serum 
concentrations of liver enzymes ( aspartate aminotransferase and alanine aminotransferase), 
iron, 17 ~-estradiol, and estrone. 
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Statistical analyses 
Statistical analyses were performed with PC SAS (Version 8, 1999; Cary, NC); 
results were considered statistically significant at P<0.05. Descriptive statistics included 
means for normally distributed data (total cholesterol, LDL cholesterol, and total/HDL 
cholesterol; age; body size and composition; blood pressure) and medians for data that were 
not normally distributed (triacylglycerol, HDL cholesterol, and Lp(a); physical activity; 
dietary intake of nutrients; coagulation/fibrinolytic factors). Repeated measures AN OVA was 
employed to determine the effect of treatment on total cholesterol, LDL cholesterol, HDL 
cholesterol, triacylglycerol, total/HDL cholesterol, and Lp(a). Cohort was included in the 
analyses as a covariate to account for random assignment of subjects to treatment within each 
cohort. Residual analysis indicated non-constancy of error variance (it increased with greater 
Y; values) for the triacylglycerol, HDL cholesterol, and Lp(a)regression models. Thus, these 
values were log-transformed for the repeated measures ANOV A and regression analyses. 
Log-transforming triacylglycerol, HDL cholesterol, and Lp(a) for the regression models 
markedly improved the residual plots·. To determine the effect of treatment on fibrinogen, 
factor VII antigen, and PAI-I, ANOVA was used, with cohort as a covariate. Since 
fibrinogen and PAI-I were not normally distributed, these values were log-transformed for 
theANOVA. 
Stepwise multiple regression was used to determine the effect of contributors for each 
outcome at baseline: total cholesterol, LDL cholesterol, HDL cholesterol, triacylglycerol, 
total/HDL cholesterol, and Lp(a) concentrations. Classes of variables in modeling the 
outcomes of lipids/lipoproteins included baseline values for age, body size/composition 
(weight, lean mass, fat mass, percentage body fat), resting blood pressure (diastolic, systolic), 
dietary factors (fat [total g and as percentage of total energy], polyunsaturated fat, fiber, 
alcohol, vitamin A, vitamin C, vitamin E, alpha-tocopherol, iron, selenium), physical 
activity, and circulating analytes (serum iron, ferritin, aspartate aminotransferase, alanine 
aminotransferase, 17 ~-estradiol, estrone, plasma PAI- I, fibrinogen, factor VII antigen). 
Factor VII coagulant activity was not included in the regression models due to the reduced 
sample size. Serum liver enzymes emerged as significant contributors and hence were 
included post-hoc. Violation of model assumptions was not evident, since residual analyses 
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indicated that the model assumptions of independence of residuals, normality of error terms, 
and homogeneity of residual variance were satisfied for these regression models. No notable 
multicollinearities emerged among the independent variables, as indicated by the low 
variance inflation factors in the regression analyses. 
RESULTS 
Compliance to dietary treatment 
The urinary excretion of isoflavones (genistein and daidzein) and self-reported 
consumption of muffins (87% of subjects consumed 100%) and powder (84% of subjects 
consumed 1 00%) in each group reflected excellent adherence to the dietary treatment. 
However, one control subject's data was removed from all subsequent analyses due to her 
urinary excretion of isoflavones during treatment being similar to women in SPI+ group. 
Detailed information on compliance is described elsewhere (Alekel et al. 2000). 
Lipid/lipoprotein and coagulation/fibrinolytic factor concentrations 
Baseline characteristics of these perimenopausal women are presented in Table 1. 
The· expected potential contributors to lipid/lipoprotein concentrations included age, body 
size and composition, physical activity, resting blood pressure, dietary intake of selected 
nutrients, plasma coagulation/fibrinolytic factors, and serum estrogens, ferritin, and iron. 
Since serum liver enzymes emerged as contributors to total cholesterol, triacylglycerol, and 
LDL cholesterol, values for these analytes at baseline are also presented. None of these 
characteristics at baseline were significantly different among treatment groups. 
Treatment had no significant effect on circulating lipids/lipoproteins (Figure 1) or 
coagulation/fibrinolytic factors as shown in Table 2. However, time had a significant effect 
on HDL cholesterol, triacylglycerol, and total/HDL cholesterol. At wk 24, HDL cholesterol 
decreased in all groups, triacylglycerol increased in the SPI+ and control groups, and 
total/HDL cholesterol increased in all groups. Changes in triacylglycero1, HDL cholesterol, 
and Lp(a) concentrations over the 24 weeks are shown in Figure 1. Although Lp(a) 
concentrations nearly doubled from baseline to wk 24 in the control group, this increase was 
not significant because of the large variability in these values, particularly for this group. The 
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increase in factor VII coagulant activity was significant (P:::0.0001) from baseline to week 24 
(Table 2). Cohort (P=0.042) had a significant effect on factor VII coagulant activity. 
Since we did not demonstrate a treatment effect, we performed further analyses to 
examine the influence of purported CVD-related factors on baseline circulating 
lipids/lipoproteins in these perimenopausal women. Coagulation factors were included as 
predictors of circulating lipid/lipoprotein models due to their established relationship in acute 
cardiovascular syndromes (Rosenson and Lowe 1998). Factors that contributed to the 
variability of total cholesterol, LDL cholesterol, HDL cholesterol, triacylglycerol, total/HDL 
cholesterol, and Lp(a) at baseline are presented in Table 3. After variable elimination was 
completed, 43% of the variability in serum total cholesterol (P,:::0.000I) was accounted for by 
serum aspartate aminotransferase, lean mass, resting diastolic blood pressure, dietary folate, 
and serum 17 ~-estradiol. Plasma PAI-I, dietary vitamin E, and serum alanine 
aminotransferase accounted for greater than 33% of the variability in serum triacylglycerol 
(P,:::0.000I). Plasma fibrinogen, serum iron, lean mass, dietary fat (g), and serum aspartate 
aminotransferase (albeit NS) accounted for more than 32% of the variability in serum LDL 
cholesterol (P=0.0003). Dietary fat(% of total energy), dietary fiber, cohort 2, dietary 
selenium, and plasma fibrinogen accounted for greater than 34% of the variability in plasma 
Lp(a) (P,:::0.000I). Fifty-seven percent of the variability in HDL cholesterol (P,:::0.0O0I) was 
accounted for by dietary vitamin E, plasma PAI-I, dietary fat(% of total energy), body 
weight, and serum ferritin. Almost 50% of the variability in serum total/HDL cholesterol 
(P,:::0.O00I) was accounted for by plasma PAI-I, dietary vitamin E, and plasma fibrinogen. 
DISCUSSION 
Dietary supplementation with SPI+ or SPI - for 24 wks did not significantly alter 
circulating lipid/lipoprotein and coagulation/fibrinolytic factor concentrations. Nonetheless, 
we identified a number of known and unconventional factors that contributed to the 
variability in lipid and lipoprotein concentrations at baseline in these perimenopausal women. 
Since postmenopausal women have increased CVD risk when compared to their 
premenopausal counterparts (Peters et al. 1999), the identification of specific risk factors is 
important in initiating preventive efforts early during the menopausal transition. To our 
knowledge, this is the only published study examining the relationship between 
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lipids/lipoproteins and coagulation/fibrinolytic factors in perimenopausal women. 
Significant changes in HDL cholesterol, triacylglycerol, and total/HDL cholesterol 
during the 24-wk period were attributed to a time effect. Thus, any effect of treatment may 
have been overshadowed by' hormonal changes during the menopausal transition, as 
evidenced by the effect of time (Table 2). Indeed, time had a significant effect (P,::::0.0001) on 
serum 17 ~-estradiol and estrone concentrations during the course of treatment. Although 
cohort did not reach statistical significance (P:::::0.060) for fibrinogen, it is noteworthy that 
season (perhaps reflected by cohort) has been shown to influence fibrinogen concentrations 
(Pearson et al. 1997). A significant effect of cohort emerged for factor VII coagulant activity. 
Cohorts 1 and 2 began in January and May, respectively, and both experienced an increase in 
factor VII coagulant activity; however, seasonal variations have not been reported to date. 
Our finding of a cohort effect may be simply due to the small sample size (N=46) for this 
particular measure. 
Plasma PAI-1 was a strong contributor to triacylglycerol, HDL cholesterol, and 
total/HDL cholesterol concentrations at baseline. Similar to the findings in our study, the 
European Concerted Action on Thrombosis (ECA T) Angina Pectoris Study has also reported 
a positive correlation between plasma triacylglycerol and PAI- activity (Juhan-Vague et al. 
1996). The underlying mechanism of the direct relationship between P AI-1 and 
triacylglycerol is unknown. However,.triacylglycerol-rich lipoproteins are known to 
stimulate PAI-I release from hepatic cells (Mussoni et al. 1992), perhaps corroborating our 
findings. The negative relationship between PAI-I and HDL cholesterol in our regression 
model is similar to the negative correlation (P,::::0.0001) reported in the ECAT Angina 
Pectoris study (Juhan-Vague et al. 1996). HDL cholesterol exhibits antioxidant properties 
through HDL-associated hydrolase, paraoxonase (Paragh et al. 1999), which may inhibit lipid 
peroxidation ofLDL particles. It is through this mechanism that HDL cholesterol may 
attenuate LDL cholesterol-induced changes in the generation of fibrinolytic regulators, such 
as P AI-1, from vascular endothelial cells (Ren and Shen 2000). Our finding of a positive 
relationship between plasma fibrinogen and LDL cholesterol has also been reported in 
population (Cremer et al. 1994; Koenig et al. 1992) and cross-sectional (M01ler and 
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Kristensen 1991; Halle et al. 1996) studies. These same population studies have reported a 
positive association between fibrinogen concentrations and Lp(a), possibly explaining in part 
the relationship of coagulation and fibrinolytic factors to atherogenesis. Fibrin, the end-
product offibrinogen conversion, provides an absorptive surface area for Lp(a) and LDL 
cholesterol to localize within plaque (Rabbani and Loscalzo 1994), perhaps illustrating Lp(a) 
and fibrinogen's involvement in atherogenesis. Researchers (M0ller and Kristensen 1991) 
have also reported a negative correlation between fibrinogen and HDL cholesterol, possibly 
corroborating our finding that fibrinogen was positively related to the total/HDL cholesterol 
ratio. The serum liver enzymes, aspartate aminotransferase and alanine aminotransferase, 
were important positive contributors to total cholesterol, triacylglycerol, and LDL 
cholesterol, suggesting that as hepatic protein synthesis increased, lipoprotein synthesis 
likewise increased (Gopal and Rosen 2000). The positive relationship of the serum liver 
enzymes coincide with the positive association of the liver-derived coagulation/fibrinolytic 
factors with the atherogenic lipids/lipoproteins, emphasizing the role of the liver in 
lipoprotein metabolism. 
Our study supports the idea that dietary factors in general were important contributors 
to circulating lipids/lipoproteins. It is well accepted that a high fat intake increases serum 
cholesterol (Goldberg and Schonfeld 1985), particularly LDL and HDL. The influence of 
dietary fat intake on Lp(a) is less well established, but we found that fat intake (as a 
percentage of total energy) was negatively related to Lp(a). It has been reported that omega-3 
fatty acids, rather than total fat as in our study, reduce Lp(a) concentrations (Hajjar and 
Nachman 1996). It may be that as percentage of total energy from fat increases, the total 
amount contributed by omega-3 fatty acids likewise increases. However, we could not 
determine whether or not this was the case in our study since Nutritionist IV did not provide 
estimates of omega-3 fatty acid intake. Although dietary selenium was also negatively related 
to Lp(a), selenium has not been shown to be related to or reduce Lp(a). However, a parallel 
effect of low selenium and LDL cholesterol has been reported in the development of CVD 
(Salonen et al. 1992). Perhaps since Lp(a) and LDL are similar in structure, this parallel 
effect may also have been seen with low selenium and Lp(a). Interestingly, dietary fiber was 
also negatively related to Lp(a), whereas its effect on Lp(a) has produced mixed results. 
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Supplementation with pectin has been shown to decrease Lp(a) (Veldman et al. 1997) 
concentrations, but oat bran (Kelley et al. 1994) or oat husk fiber (Sundell and Ranby 1993) 
does not. These dietary influences on Lp(a) should be further explored. Vitamin E had a 
positive impact on triacylglycerol, HDL cholesterol, and total/HDL cholesterol 
concentrations, perhaps signifying the role of vitamin E in quenching lipid peroxidation 
(Henning and Alvarado 1993). Vitamin E administration has been documented to reduce 
lipid peroxide within cells, which leads to increased hepatic uptake oftriacylglycerol-rich 
lipoproteins (Staprans et al. 1993). Finally, the negative relationship between total cholesterol 
and dietary folate may reflect its role in lowering homocysteine concentrations (Fanapour et 
al. 1999), although the direct connection between dietary folate and risk of coronary· artery 
disease is debated (Siri et al. 1998; Boushey et..al. 1995). Nonetheless, elevated homocysteine 
concentrations may damage vascular endothelial cells, thereby allowing damage and lipid 
accumulation (Fanapour et al. 1999), paralleling circulating lipid concentrations. 
Most studies have reported the positive relationship between total cholesterol and fat 
mass (Rosenfalck et al. 1996), but our study demonstrated the negative relationship between 
lean mass and total cholesterol or LDL cholesterol, suggesting that lean mass per se may 
exert protective effects. Perhaps the effect of lean mass on lipids has not been reported 
because lean mass is typically not assessed, but rather fat mass ( or percentage body fat) or 
another index of body mass is usually reported. In our study, BMI was negatively related (r=-
0.38; P=0.001) to HDL cholesterol, but did not remain as a significant contributor to overall 
HDL cholesterol once additional factors were considered. Simple correlations between BMI 
or fat mass and other circulating lipids were less impressive. However, body weight was a 
significant contributor to HDL cholesterol; the inverse relationship in our study has been 
previously reported (Glueck et al. 1980; Hayashi et al. 1987; Chen et al. 1983). It is not 
surprising that physical activity did not emerge as a contributor to any lipicl/lipoprotein, since 
this was not an exercise intervention study. The finding that resting blood pressure was 
directly related (r=0.32; P=0.0008) to total cholesterol may be corroborated by the 
association of reduced LDL cholesterol with the improvement in endothelium-dependent 
vasoreactivity in response to cholesterol-lowering drugs (Cohen et al. 2000). Elevated blood 
pressure can cause extravasations of plasma into the arterial wall, thus contributing to 
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cholesterol accumulation and the progression of atherosclerosis. Since the arterial wall 
cannot fully degrade and metabolize the build-up (Chappell and Spector 1991), cholesterol 
accumulates. However, we did not examine arterial cholesterol concentrations or 
vasoreactivity in this study. 
The negative relationship between serum ferritin and HDL cholesterol has been 
previously reported (Salonen et al. 1992). Our results indicate that with higher iron stores (as 
reflected by circulating ferritin), HDL cholesterol was negatively affected, perhaps an 
• indication of greater lipid peroxidation and hence greater removal of oxidized HDL particles 
via scavenger-receptor BI (Van Berke! et al. 2000). Although the iron bound to ferritin does 
not dissociate readily, perhaps it is.a source ofiron for redox reactions (Salonen 1993). 
Likewise, the negative relationship between serum iron and LDL cholesterol may be 
explained by the effect of iron on cholesterol oxidation. As serum iron increases, LDL 
cholesterol oxidation may also increase, thus leading to greater uptake of modified LDL 
particles by scavenger receptor pathways (Regnstrom et al. 1994). This in turn might have a 
cholesterol.:lowering effect, explaining the negative relationship of serum iron and LDL 
cholesterol. However, since we did not document this same relationship for total cholesterol 
and LDL cholesterol is a calculated value, one must view these results with caution. 
Our finding that serum 17 f3-estradiol was negatively associated with total cholesterol 
(Pearson correlation: r = -0.25; P=0.038) at baseline was shown in other studies (Vagenakis 
1989; Bonithon-Kopp et al. 1990) and illustrates the antiatherogenic role of estrogen. 
Throughout menopause, 17 f3-estradiol concentrations decline (Cauley et al. 1989), thereby 
reducing the cardioprotective effect of estrogen in the peri- and postmenopausal years. 
In hindsight, the stage at which we obtained blood samples may be too early in the 
menopausal transition to show marked adverse effects on circulating lipids/lipoproteins or 
coagulation/fibrinolytic factors, thus making it more difficult to demonstrate an effect of 
treatment. Matthews et al. (1994) reported that perimenopausal women did not have more 
adverse lipid/lipoprotein profiles when compared with premenopausal controls. However, 
significant changes have been noted once perimenopausal women become postmenopausal 
(Matthews et ~1. 1994), suggesting that our six-month study did not continue long enough 
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into the early postmenopausal stage to have captured potential treatment-induced changes in 
the lipid/lipoprotein profile. 
In conclusion, treatment for 24 wks with SPI+ or SPI - did not alter lipid/lipoprotein 
or coagulation/fibrinolytic factor concentrations in these perimenopausal women. However, 
lean body mass, serum 17 B-estradiol, and dietary factors (vitamin E, selenium, fiber, and 
folate) favorably contributed to lipid profiles, whereas plasma fibrinogen and PAI-1, diastolic 
blood pressure, body weight, serum liver enzymes, and serum ferritin adversely affected 
circulating lipid and lipoprotein concentrations. 
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TABLE 1 
Baseline characteristics in perimenopausal women 
Measurement (n=69) 
Age (years) 
Height (cm) 
Weight (kg) 
BMI (kg/m2) 
Lean mass (kg) 1 
Body fat (%)1 
Physical activity (MJ; median [min-max]) 
Resting blood pressure 
Systolic (mmHg) 
Diastolic (mmHg) 
Mean+SD 
[min-max] 
50.2+3.6 
[41.9-61.6] 
164.8+5.0 
[151.6-177.5] 
65.3+9.0 
.. [48.5-98.1] 
24.1+3.2 
[17.4-33.7] 
39.8+6.8 
[31.4-48.6] 
37.2+6.3 
[18.4-53.1] 
4.33 
[0.17-17.14] 
119+11 
[100-144] 
71+10 
[54-98] 
TABLE 1 ( continued) 
D. . t k 2 3 1etary ma e' 
Energy (MJ) 
Fat (g) 
Fat(% of total energy) 
Saturated fat (g) 
Polyunsaturated fat (g) 
Dietary fiber (g) 
Vitamin C (mg) 
Vitamin E (mg) 
Vitamin A (RE) 
Folate (µg) 
Selenium (mg) 
59 
Median 
[min-max] 
7.46 
[4.07-10.64] 
59.4 
[26.8-99.8] 
30.2 
[14.8-45.8] 
18.7 
[7.6-48.4] 
10.5 
[2.8-20.6] 
18.7 
[4.1-51.2] 
116.8 
[27.8-586.2] 
10.7 
[1.5-29.7] 
1015.5 
[195.1-4732.0] 
246 
[74-725] 
0.045 
[0.004-0.097] 
TABLE 1 ( continued) 
Alcohol intake (g)4 
Serum 
Aspartate aminotransferase (µkat/L) 
Alanine aminotransferase (µkat/L) 
Estrone (pmol/L) 
17 13-estradiol (pmol/L) 
Ferritin (µg/L) 
Iron (µmol/L) 
1 Assessed by dual energy x~ray absorptiometry 
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162.l 
[0.8-1131.3] 
0.35 
[0.23-1.08] 
0.22 
[0.05-1.68] 
122.1 
[37.0-447.6] 
150.5 
[73.4-785.6] 
17.0 
[0.4-210.0] 
15.9 
[1.4-29.7] 
2 Median values are reported for serum analytes and dietary intake, since most were not normally distributed 
3 Dietary intake was assessed from 5-d food diaries collected prior to baseline testing 
4 Refers to 33 women who reported that they consumed alcohol during the recording of the 5-d food diary 
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FIGURE 1. Change in HDL cholesterol (HDL-C), triacylglycerol (TG), and lipoprotein(a) [Lp(a)] 
concentrations (median) in perimenopausal women from baseline to week 24 according to treatment: 
isoflavone-rich soy protein isolate (SPI+ = n = 24), isoflavone-poor soy protein isolate (SPI - = 
n = 24), and whey protein (control=•; n = 21). 
TABLE2 
Lipid/lipoprotein concentrations at baseline, wk 12, and wk 24 and and coagulation/fibrinolytic concentrations at baseline and wk 
24 in perimenopausal women 
Measure lsoflavone-rich soy lsoflavone-poor soy protein Whey protein ANOVN 
(mean±SD or protein (SPI+) (SPI-) (control) (Pvalues) 
median [min-max]) Base Wk12 Wk24 Base Wk12 Wk24 Base Wk12 Wk24 Tx3 Time Cohort 
Total cholesterol 5.42 5.36 5.43 5.62 5.55 5.47 5.49 5.28 5.47 0.62 0.60 0.19 
(mmol/L)2 ±0,65 ±0,69 ±0,66 :!: 1.03 ±0,92 :!: 1.08 ±0,87 ±0,81 ±1.04 
LDL cholesterol 3.27 3.27 3.43 3.49 3.43 3.51 3.48 3.30 3.52 0.63 0.12 0.26 
(mmol/L)2 ±0,54 ±0.50 ±0.54 ±0,89 ±0,76 ±0,97 ±0,83 ±0,82 ± 1.01 
Total/Bl)L 3.62 3.54 3.86 3.83 3.60 3.95 3.76 3.51 3.94 0.91 :::_0.0001 0.17 0\ N 
cholesteroi2 ±0,90 ±0,76 ±0,94 ± 1.16 ±0,78 ±0,99 ± 1.08 ±0,72 ± 1.02 
Base Wk24 Base Wk24 Base Wk24 Tx3 Cohort 
Fibrinogen (g/L )4·6 3.3 3.5 3.2 3.2 3.3 3.1 0.29 . 0.060 
[2.5-4.6] [2.6-4.4] [1.4-4.5] [2.7-4.2] [2.5-4.1] [2.5-4.8] 
Factor VII antigen 79.4 76.8 74.1 75.0 79.4 77.4 0.54 0.61 
(%)6 ± 12.1 ± 12.3 ±12.0 ± 15.8 ± 11.6 ± 10.9 
TABLE 2 (continued) 
Base Wk24 Base Wk24 Base Wk24 
Factor VII coagulant 46.4 76.7 42.4 73.4 58.3 101.8 
activity (%) 7 . ±32.5 ±33.4 ±30.6 ±39.6 ±40.3 ±54.7 
Plasminogen activator 283.4 283.4 333.4 300.1 216.7 216.7 
inhibitor-! 
(µkat/L)4,8 
[66.7-550] [16.7-1234] [150.0-734] [183.4-700] [100.0-684] [l 00.0-517] 
1 Repeated measures ANOV A performed on lipids/lipoproteins; ANOV A performed on coagulation/fibrinolytic factors 
2 SPI+ (n = 24); SPI - (n = 24); control (n = 21); total N = 69 
3 Tx = Treatment 
Tx3 Cohort 
0.60 0.042 
0.80 0.80 
4 Median values are reported for fibrinogen, and plasminogen activator inhibitor-I because they were not normally distributed; log-transformed values of 
these same variables were then used for the ANOV A 
5 S~I+ (n = 23); SPI - (n = 24); control (n = 20); total N = 67 
6 SPI+ (n = 20); SPI. (n = 23); control (n = 21); total N = 64 
7 SPI+ (n = 16); SPI. (n = 15); control (n = 15); total N = 46; factor VII coagulant activity increased (P:::0,0001) from baseline to wk 24 
8 . SPI+ (n = 21); SPI - (n = 23); control (n = 21); total N = 65 
°' v-' 
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TABLE3 
Regression analyses: Contributors to lipid/lipoprotein concentrations at baseline 
Total Cholesterol: Overall Model R2=43.3% (Adj R2=38.8%); F (5, 63)=9.61; 
(p ~0.0001) 
Independent Variable Parameter Percentage Variance 
Estimate V . 1 ar1ance Pvalue2 Inflation3 
Intercept 6.3666 ~0.0001 
Serum aspartate aminotransferase 2.5454 10.33 0.0012 1.03 
Lean mass -0.0652 7.67 0.0049 1.03 
Resting diastolic bh>0d pressure 0.0220 6.28 0.010 1.02 
Dietary folate -0.0020 6.21 0.011. 1.02 
Serum 17 D-estradiol -0.0010 4.04 0.038 1.03 
Triacylglycerol4: Overall Model R2=33.8% (Adj R2=30.6%); F (3, 61)=10.39; 
(p 0.0001) 
Intercept -0.2257 0.18 
Plasma plasminogen inhibitor activator-I 0.0013 13.38 0.0008 1.14 
Dietary vitamin E -0.0231 7.36 0.012 1.23 
Serum alanine aminotransferase 0.5964 4.42 0.048 1.20 
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TABLE 3 ( continued) 
LDL cholesterol: Overall Model R2=32.3% (Adj R2=26.5%); F (5, 58)=5.54; (p=0.0003) 
Independent Variable Parameter Percentage Variance 
Estimate Variance Pvalue Inflation 
Intercept 3.7097 0.0056 
Plasma fibrinogen 0.4246 8.70 0.0084 1.11 
Serum iron -0.0383 7.22 0.016 1.08 
Lean mass -0.0576 7.11 0.017 1.04 
Dietary fat (g) 0.0106 4.95 0.050 1.15 
Serum aspartate aminotransferase 1.4595 4.29 0.060 1.02 
Lipoprotein( a )4: Overall Model R2=34.8% (Adj R2=29.2%); F (5, 58)=6.20; (p:: 0.0001) 
Intercept 5.2256 ::::0.0001 
Dietary fat (% of total energy) -0.0711 12.39 0.0016 1.44 
Dietary fiber -0.0434 8.41 0.0082 1.41 
Cohort2 0.6061 6.11 0.023 1.09 
Dietary selenium -12.8457 5.91 0.026 1.12 
Plasma fibrinogen 0.4487 5.38 0.033 1.09 
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TABLE 3 ( continued) 
HDL cbolestero14: Overall Model R2=56.5% (Adj R2=52.9%); F (5, 59)=15.35; 
(p :S 0.0001) 
Independent Variable Parameter Percentage Variance 
Estimate Variance Pvalue Inflation 
Intercept 0.4779 0.0207 
Dietary vitamin E . 0.0142 13.62 <0.0001 1.10 
Plasma plasminogen activator inhibitor-1 -0;0005 7.77 0.0019 1.17 
Dietary fat (% of total energy) 0.0108 7.01 0.0031 1.05 
Body weight (kg) -0.0056 3.76 0.028 1.11 
Serum f erritin -0.0014 3.50 0.033 1.04 
Total Cbolesterol/HDL cholesterol: Overall Model R2=49.9% (Adj R2=47.4%); 
F (3, 60)=19.92; (p :s 0.0001) 
Intercept 1.4014 0.023 
Plasma plasminogen activator inhibitor-1 0.0028 16.56 :::0.0001 1.09 
Dietary vitamin E -0.0522 10.72 0.0007 1.06 
Plasma fibrinogen 0.6112 10.61 0.0007 1.04 
1 Squared semi-partial Type II correlation coefficient; accounts for shared variance among variables 
67 
TABLE 3 ( continued) 
2 Variables left in models are significant at P 0.10 level 
3 Measures inflation in the variances of parameter estimates due to multicollinearities among regressors 
4 Models were log-transformed since HDL cholesterol, triacylglyceridol, and lipoprotein(a) were not normally 
distributed 
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· GENERAL CONCLUSIONS 
In summary, the results from the primary objective of this study suggest that 
isoflavone-rich or isoflavone-poor soy protein do not favorably alter circulating lipids and 
· lipoproteins or coagulation and fibrinolytic factors in perimenopausal women. Thus, the 
inclusion of soy products to the diets of perimenopausal women is not likely an appropriate 
alternative to hormone replacement therapy for women at-risk for CVD. To verify this 
finding, the influence of isoflavone-rich soy protein on other CVD risk factors needs to be 
examined. The results from the secondary objective determined that lean body mass, serum 
17 13-estradiol, and dietary factors (vitamin E, selenium, fiber, and folate) favorably 
contributed to lipid profiles, whereas plasma fibrinogen and P AI-1, diastolic blood pressure, 
body weight, serum liver enzymes, and serum ferritin adversely affected circulating lipid and 
lipoprotein concentrations at baseline. 
Future data analysis will be conducted to determine the relationship between 
isoflavone-rich and isoflavone-poor soy protein and antioxidant status, since isoflavones 
have antioxidant properties. We will also account for the contributors of dietary (fat, 
antioxidants, fiber, alcohol) and serum (estrogen, iron, ferritin) factors in determining total 
antioxidant status in these perimenopausal women. 
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